AD-A240 490

AAMRL-TR-90-070

GENOTOXICITY ASSESSMENT OF PERFLUORODECANOIC ACID USING A BATTERY OF *IN VITRO* AND *IN VIVO/IN VITRO* ASSAYS

C. S. Godin

NSI TECHNOLOGY SERVICES CORPORATION
P. O. BOX 31009
DAYTON, OH 45431-0009

B. C. Myhr
T. E. Lawlor
R. R. Young
H. Murli
M. A. Cifone

HAZLETON LABORATORIES AMERICA, INC.
5516 NICHOLSON LANE
KENSINGTON, MD 20895

DTIC
ELECTE
SEP 18 1991
S D
D

91-10949

DECEMBER 1990

FINAL REPORT FOR THE PERIOD OCTOBER 1989 THROUGH DECEMBER 1990

20030211046

HARRY G. ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY
HUMAN SYSTEMS DIVISION
AIR FORCE SYSTEMS COMMAND
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433-6573

91 9 18 003

TECHNICAL REVIEW AND APPROVAL

AAMRL-TR-90-070

The experiments reported herein were conducted according to the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE COMMANDER

JAMES N. McDOUGAL, Maj, USAF, BSC
Deputy Director, Toxic Hazards Division
Harry G. Armstrong Aerospace Medical Research Laboratory

REPORT DOCUMENTATION PAGE

1. AGENCY USE ONLY (Leave Blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	December 1990	FINAL REPORT-October 1989-December 1990

4. TITLE AND SUBTITLE

Genotoxicity Assessment of Perfluorodecanoic Acid Using a Battery of In Vitro and In Vivo/In Vitro Assays

6. AUTHOR(S)

C. S. Godin, B. C. Myhr, T. E. Lawlor, R. R. Young, H. Murli, M. A. Cifone

5. FUNDING NUMBERS

PE	61102F
PR	2312
TA	2312V1
WU	2312V11B Accession #320700

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

NSI Technology Services Corporation
P.O. Box 31009
Dayton, OH 45431-0009

8. PERFORMING ORGANIZATION REPORT NUMBER

AAMRL-TR-90-070

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)

AAMRL, Toxic Hazards Division
HSD, AFSC
Wright-Patterson AFB, OH 45433-6573

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release; distribution is unlimited.

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

Perfluoro-n-decanoic acid (PFDA), a perfluorinated fatty acid was evaluated in *in vitro* bioassays to assess its potential genotoxic activity. The assays conducted were the Ames *Salmonella*/microsomal mutagenicity assay, the Chinese hamster ovary (CHO) gene mutation assay, the CHO/sister chromatid exchange (SCE) and chromosome aberrations assays, the BALB/c-3T3 cell transformation assay and *in vivo/in vitro* unscheduled DNA (UDS) and S-phase synthesis assays. The results of the genetic tests indicated that PFDA does not interact with genetic material except possibly at highly toxic doses. No responses were found in the Ames assay, SCE assay, and cell transformation assay. However, in the chromosomal aberrations assay highly toxic treatments of cells in culture with PFDA induced a dose-related increase in chromosomal aberrations in the presence of S9 microsomal enzymes. PFDA also caused an increase in S phase DNA synthesis at both 16 and 48 hours after dosing. The maximum response was obtained at a dose of 22 mg/kg. At both higher and lower concentrations the response was decreased. These responses indicated the rapid onset of a low-level hepatotoxicity but the genetic test battery results predicted that little or no genetic risk would occur from exposure to PFDA.

14. SUBJECT TERMS

Ames Assay, Chromosomal Aberration, Hepatotoxicity, Mutagenicity, Perhalogenated Fatty Acid, Perfluorodecanoic Acid, Sister Chromatid Exchange, S-Phase DNA Synthesis, Transformation, Unscheduled DNA Synthesis

15. NUMBER OF PAGES

81

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
UNCLASSIFIED	UNCLASSIFIED	UNCLASSIFIED	UL

PREFACE

The research reported in this document was conducted by Hazleton Laboratories America, Inc. under a subcontract to NSI Technology Services Corporation in support of the Toxic Hazards Research Unit (THRU). The THRU is the contractor-operated effort of the Toxic Hazards Division of the Harry G. Armstrong Aerospace Medical Research Laboratory located at Wright-Patterson Air Force Base, OH. During the initiation and conduct of these studies Lt Col Michael B. Ballinger and Maj James N. McDougal served consecutively as the contract technical monitor.

The experimental work reported here was begun on 30 October 1989 and completed 10 December 1990. The genotoxicity assays were conducted at the Hazleton Laboratories America facilities in Kensington, MD. The results of their work were reported to NSI in separate reports on each assay. These reports were edited by NSI and organized such that the results of each assay are provided in a separate paper. Each paper is authored by the investigator who conducted the study and a summary (Section 2) is provided to collectively consider the results from the individual studies. The final reports received from Hazleton Laboratories, copies of the raw data, Quality Assurance Statements, and Good Laboratory Practice Compliance and Certification Statements for each of the studies will be archived in the Quality Assurance Archive of the THRU.

The use of trade names in this report does not constitute an official endorsement or approval of the use of such commercial hardware or software. This report may not be cited for the purposes of advertisement.

TABLE OF CONTENTS

SECTION

PAGE

LIST OF TABLES

4

ABBREVIATIONS

AF	Acentric fragment
BrdU	5-Bromo-2'deoxyuridine
°C	Degrees Centigrade
CE	Cloning efficiency
CHO	Chinese hamster ovary
Ci	Curies
cm	Centimeter
CoA	Coenzyme A
CP	Cyclophosphamide
CTFE	Chlorotrifluoroethylene
DMN	Dimethylnitrosamine
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
EMEM	Eagles's minimum essential medium
F-344	Fischer 344
FBS	Fetal bovine serum
FPG	Fluorescence-plus-Giemsa
g	Gram
h	Hour
HGPRT	Hypoxanthine-guanine phosphoribosyl transferase
^{3}HTdr	Tritiated thymidine
ip	Intraperitoneal
kg	Kilogram
M	Molar
MCA	3-Methylcholanthrene
μCi	Microcurie
μg	Microgram
μL	Microliter
μM	Micromolar
mg	Milligram
min	Minute
mL	Milliliter
mm	Millimeter
mM	Millimolar
MMC	Mitomycin C
NADP	Nicotinamide adenine dinucleotide phosphate
NADPH	Reduced nicotinamide adenine dinucleotide phosphate
NNG	Net nuclear grains
NTP	National Toxcicology Program
p	Probability
PBS	Phosphate buffered saline
%	Percent
pCTFE	Polychlorotrifluoroethylene
PFDA	Perfluoro-n-decanoic acid
PFOA	Perfluoro-n-octanoic acid
RI	Replicative index
rpm	Revolutions per minute
SCE	Sister chromatid exchange
SD	Standard deviation
SE	Standard error
TG	6-Thioguanine
THRU	Toxic Hazards Research Unit
U	Units
UDS	Unscheduled DNA synthesis

5

UV	Ultraviolet
v/v	Volume per volume
VC	Vehicle control
w/v	Weight per volume
xg	Forces of gravity

SECTION 1

INTRODUCTION

C. S. Godin

Chemicals that are structural analogs of the hypolipidemic agent, clofibrate (Lalwani et al., 1983) and industrial chemicals such as phthalate ester plasticizers and phenoxy acid herbicides (Reddy et al., 1976; Kawashima et al., 1984) induce hepatomegaly and a large increase in the number of hepatocytic peroxisomes as well as changes in their enzyme content (Moody and Reddy, 1978; Reddy and Lalwani, 1983). Peroxisome proliferation has been correlated with hepatocarcinogenic potency (Reddy et al., 1980; Elcombe, 1985) and it has been suggested that peroxisome proliferators promote tumor formation by inducing oxidative stress (Reddy and Lalwani, 1983; Reddy and Rao, 1987; Rao and Reddy, 1987) or by providing a mitogenic stimulus (NTP, 1982; Ciriolo et al., 1982; Ward et al., 1984; Marsman et al., 1988) resulting in an increase in the amount of S-phase DNA synthesis.

The perfluorinated carboxylic acid, perfluoro-n-decanoic acid (PFDA), has previously been shown to cause hepatomegaly (Olson et al., 1982), peroxisome proliferation (Ikeda et al., 1985; Van Rafelghem, 1985) and a 20- to 40-fold increase in fatty acyl-CoA oxidase activity, the rate-limiting enzyme in the fatty acid oxidase system (Harrison et al., 1988). Therefore, perfluorinated carboxylic acids may represent a new class of carcinogenic compounds although there has been no evidence to suggest that PFDA can promote the formation of preneoplastic lesions (Robertson, personal communication) or that it is tumorigenic. Of particular interest then, is the recent finding that perfluoro-n-octanoic acid (PFOA) administration resulted in a 33% incidence in hepatocellular carcinoma seven months after initiation and growth-selection with 2-acetylaminofluorene in male Wistar rats (Abdellatif et al., 1990). In that study, PFOA also resulted in a 24-fold elevation in the peroxisomal β-oxidation of fatty acids. These authors have suggested that the induction of peroxisomal fatty acid oxidation is consistent with the hypothesis that oxidative stress is important in tumor promotion by this class of compounds

While the administration of peroxisome proliferators has been correlated with tumor formation they have not, as a class, demonstrated genotoxic effects (Warren et al., 1980; Gupta et al., 1985). However, because PFDA is representative of a potentially new class of carcinogens and to more fully evaluate the potential human health hazards of these compounds, *in vitro* and *in vivo* tests were conducted to determine their genotoxic potential.

REFERENCES

Abdellatif, A.G., V. Preat, J. Vamecq, R. Nilsson, and M. Roberfroid. 1990. Peroxisome proliferation and modulation of rat liver carcinogenesis by 2,4-dichlorophenoxyacetic acid, 2,4,5-trichlorophenoxyacetic acid, perfluorooctanoic acid and nafenopin. *Carcinogenesis* 11:1899-1902.

Ciriolo, M.R., I. Mavelli, G. Rotilio, V. Borzatta, M. Cristofari, and L. Stanzani. 1982. Decrease of superoxide dismutase and glutathione peroxidase in livers of rats treated with hypolipidemic drugs. *FEBS Lett.* 144:264-268.

Elcombe, C.R. 1985. Species differences in carcinogenicity and peroxisome proliferation due to trichloroethylene: A biochemical human hazard assessment. *Arch. Toxicol.* 8(Suppl.):6-17.

Gupta, R.C., S.K. Goel, K. Early, B. Singh, and J.K. Reddy. 1985. ^{32}P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver *in vivo* and hepatocytes *in vitro*. *Carcinogenesis* 6:933-936.

Harrison, E.H., J.S. Lane, S. Luking, M.J. Van Rafelghem, and M.E. Andersen. 1988. Perfluoro-*n*-decanoic acid: Induction of peroxisomal ß-oxidation by a fatty acid with dioxin-like toxicity. *Lipids* 23:115-119.

Ikeda, F., K. Aiba, K. Fukuda, and M. Tanaka. 1985. The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. *J. Biochem.* 98:475-432.

Kawashima, Y., H. Katoh, S. Nakajima, H. Kozuka, and M. Uchiyama. 1984. Effects of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid on peroxisomal enzymes in rat liver. *Biochem. Toxicol.* 33:241-245.

Lalwani, N.D., M.K. Reddy, S.A. Qureshi, C.R. Sartori, Y. Abiko, and J.K. Reddy. 1983. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. *Human Toxicol.* 2:27-48.

Marsman, D.S., R.C. Cattley, J.G. Conway, and J.A. Popp. 1988. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di (2-ethylhexyl)-phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrmidinylthio]acetic acid (Wy-14,643) in rats. *Cancer Res.* 48:6739-6744.

Moody, D.E. and J.K. Reddy. 1978. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid and WY-14643) on hepatic peroxisomes and peroxisome associated enzymes. *Am. J. Pathol.* 90:435-446.

National Toxicology Program (NTP). 1982. Carcinogenesis Bioassay of Di(2-ethylhexyl)phthalate in F-344 Rats and B6C3F1 Mice. NIH Publ. No. 82-1773.

Olson, C.T., M.E. Andersen, M.E. George, M.J. Van Rafelghem, and A.M. Back. 1982. The toxicology of perfluorodecanoic acid in rodents. AAMRL-TR-82-101. Proceedings of the Thirteenth Annual Conference on Environmental Toxicology, Air Force Aerospace Medical Research Laboratory,Wright-Patterson Air Force Base, OH, p287-303.

Rao, M.S. and J.K. Reddy. 1987. Peroxisome proliferation and hepatocarcinogenesis. *Carcinogenesis* 8:631-636.

Reddy, J.K., D.E. Moody, D.L. Azarnoff, and M.S. Rao. 1976. Di(2-ethylhexyl)-phthalate: An industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rats and mice. *Life Sce.* 18:941-946.

Reddy, J.K., D.L. Azarnoff, and C.E. Hignite. 1980. Hypolipidemic hepatic peroxisome proliferator: form a novel class of chemical carcinogens. *Nature* (London) 283:397-398.

Reddy, J.K. and N.D. Lalwani. 1983. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. *CRC Crit. Rev. Toxicol.* 12:1-58.

Reddy, J.K. and M.S. Rao. 1987. Peroxisome proliferators and cancer: Mechanisms and implications. *Trends Pharmacol. Sci.* 7:438-443.

Van Rafelghem, M.J. 1985. The Toxicity and Hepatic Ultrastructure Effects of Perfluoro-*n*-decanoic Acid in Four Rodent Species. Dissertation. Fairborn, OH: Wright State University.

Ward, J.M., M. Ohshima, P. Lynch, and C. Riggs. 1984. Di(2-ethylhexyl)-phthalate but not phenobarbital promotes *N*-nitrosodiethylamine-initiated hepatocellular proliferative lesions after short-term exposure in male B6C3F1 mice. *Cancer Lett.* 24:49-55.

Warren, J.R., V.F. Simmon, and J.K. Reddy. 1980. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [^{3}H]thymidine and *Salmonella* mutagenesis assays. *Cancer Res.* 40:36-41.

SECTION 2

PFDA GENOTOXICITY SUMMARY EVALUATION

B.C. Myhr

The compound, nonadecafluorodecanoic acid (perfluorodecanoic acid, PFDA), was tested for potential genotoxic activity by application to several *in vitro* assays, as described below, and to a sensitive *in vivo* assay for DNA damage and cytotoxicity in the liver. The substance was supplied as white, crystalline flakes, which were found to be soluble in dimethylsulfoxide (DMSO) at concentrations as high as 500 mg/mL. Solutions were prepared in DMSO just prior to use in each *in vitro* assay. Glass containers and pipets were used, and the treatments of mammalian cells *in vitro* were conducted in glass flasks. After dilution of the stock solutions into culture medium, complete solubility was maintained at concentrations above 1000 μg/mL; a slight cloudiness was noted at a concentration of 5000 μg/mL. For the *in vivo* assay, PFDA was suspended in corn oil and mechanically homogenized, then administered by oral gavage.

The Ames *Salmonella* reverse mutation assay was performed by the preincubation method in order to maximize the interaction between the bacteria and PFDA. Strains TA98, TA100, TA1535, TA1537, and TA1538 were used in the presence and absence of a rat liver S9 metabolic activation system (Aroclor 1254-induced). PFDA was only slightly toxic over a dose range of 333 to 10,000 μg/plate without the addition of S9; with S9, no toxicity was observed. The induction of revertants was assayed in cultures exposed to a series of doses up to 10,000 μg/plate under both test conditions. No increase in revertants was obtained. Therefore, PFDA showed no detectable mutagenic activity in this bacterial system.

In mammalian cell culture, PFDA was tested for mutagenic activity at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus in Chinese hamster ovary (CHO) cells. After a 4-h exposure period, with and without S9 activation, the compound showed little toxicity up to a concentration of 125 μg/mL, but became highly toxic at a concentration of 250 μg/mL. The mutation assay conducted without the addition of S9 was performed over a dose range of 10 to 160 μg/mL and yielded a wide survival range of 9 to 99%. No significant increase in mutant frequency was obtained. With S9, two trials were performed in order to achieve a survival range of from 18 to 117%. The doses ranged from 5 to 160 μg/mL; a concentration of 200 μg/mL was excessively toxic. No significant increase in mutant frequency was obtained in either trial. Therefore, PFDA was toxic to cultured CHO cells but did not induce any detectable mutagenesis at the HGPRT locus.

CHO cells were also examined for cytogenetic damage in assays for chromosomal aberrations and sister chromatid exchanges (SCEs) after treatment with PFDA. The compound was highly toxic at a concentration of 167 μg/mL without the addition of S9; SCE analysis at this dose was not possible. Little or no toxicity was obtained at a concentration of 50 μg/mL, and no delay in cell cycle was observed. Analysis of SCE over a dose range of 1.67 to 50 μg/mL showed no significant increase. No increase in chromosomal aberrations was obtained over a dose range of 75 to 200 μg/mL, using a normal 10-h harvest. With the 2-h treatment in the presence of S9, PFDA was lethal at a concentration of 501 μg/mL and highly toxic at a concentration of 167 μg/mL, causing severe cell cycle delay. Accordingly, a delayed harvest time of 20 h was used for doses of 100 μg/mL and higher. SCEs were assayed over a dose range of 5 to 167 μg/mL, and no dose-related increase was obtained. Chromosomal aberrations were not observed at concentrations of 75

10

and 100 µg/mL, but a dose-related response was obtained at concentrations of 151 and 201 µg/mL. The increase that occurred at a concentration of 201 µg/mL was highly significant and was characterized by complex chromatid types of aberrations often observed for chemical clastogens. Thus, PFDA did not cause DNA damage as indicated by the lack of SCE response, but clastogenic activity was clearly indicated in the presence of S9.

An *in vivo* assessment of genetic activity was performed by dosing male F-344 rats with four doses of PFDA ranging from 5.5 to 44 mg/kg. After single oral administrations, primary hepatocyte cultures were established to determine the degree of DNA repair (unscheduled DNA synthesis, UDS) and DNA replication (S-phase) by labeling with ^{3}H-thymidine (^{3}HTdr), followed by autoradiographic analysis. The cultures were prepared 15-18 h after treatment of the animals for the UDS analysis and approximately 48 h after treatment of additional animals for S-phase analysis. None of the treatments caused any increase in nuclear labeling or the percent of cells in DNA repair relative to control rats. Therefore, PFDA did not induce any detectable UDS. However, evidence for liver toxicity was obtained from the S-phase analysis. A maximum average response of 2.2% cells in S-phase was obtained at a dose of 22 mg/kg, compared to the value of 0.4% in control rats. This response was decreased in animals exposed to the high and lower dose. A very similar response with a peak at 22 mg/kg was observed in the UDS assay. These increases in hepatocyte DNA replication indicated a rapid response to hepatotoxicity caused by the treatments with PFDA.

PFDA was assayed for its ability to induce morphological transformation in cultures of mouse BALB/c-3T3 cells, both in the presence and absence of a rat liver S9 metabolic activation system. The treatments were for 2 h with S9 and 72 h without S9, and two or three independent trials were conducted under each test condition. Clonal survival was determined from the use of ouabain-resistant cells in the presence of the wildtype monolayer cultures. The compound was lethal at concentrations of 100 µg/mL without S9 and 1000 µg/mL with S9; halving the concentrations resulted in little or no toxicity, so the survival was characterized by a precipitous drop over a narrow concentration range. Two transformation assays without S9 were performed over an inclusive concentration range of 50 to 120 µg/mL, which resulted in a survival range of 16 to 103%. No significant change in the frequency of transformed foci was obtained in either trial. Three trials were conducted with the addition of S9 in order to determine the effects of high, intermediate, and low toxicities. The inclusive concentration range was 50 to 500 µg/mL, and survivals ranged from apparantly 0 to 112%. A sufficient number of cells survived the treatment with 500 µg/mL to form a complete monolayer and afford analysis for foci. The frequency of transformed foci did not change significantly from the control cultures in any of the trials. Therefore, no evidence was obtained for transforming activity by PFDA.

The results of the above genetic tests indicated that PFDA does not interact with genetic material, except possibly at highly toxic doses. No responses were found in the *in vitro* tests for mutagenicity, DNA damage (SCE induction), and cell transformation. In the presence of S9, highly toxic treatments did induce a dose-related increase in chromosomal aberrations. The mechanism of this genetic alteration remains unknown and could be related to indirect effects on chromosome stability caused by toxic actions other than at the level of DNA. The *in vivo* study of rat liver response to PFDA indicated the rapid onset of a low-level hepatotoxicity but no detectable damage to the DNA. Thus, the results of the genetic test battery would predict little or no

genetic risk from exposures to PFDA. Highly toxic exposures could induce some chromosomal damage, and ingestion of PFDA could result in slight physiological stress to the liver.

MUTAGENICITY TEST ON PFDA IN THE *SALMONELLA*/REVERSE MUTATION ASSAY (AMES TEST) PREINCUBATION METHOD

T.E. Lawlor

INTRODUCTION

The mutagenic activity of PFDA was examined in the *Salmonella*/Reverse Mutation Assay (Ames Test), Preincubation Method. This assay evaluated the test article and/or its metabolites for their ability to induce reverse mutations at the histidine locus in the genome of specific *Salmonella typhimurium* tester strains both in the presence and absence of an exogenous metabolic activation system of mammalian microsomal enzymes derived from Aroclor-induced rat liver.

The Ames Test detects both frameshift and/or base pair substitution point mutations in bacteria and has been shown to be a sensitive, rapid, and accurate indicator of the mutagenic activity of many materials including a wide range of chemical classes. Both base pair substitution mutations and frameshift mutations can be detected by utilizing several different tester strains. Tester strains TA98, TA1537, and TA1538 are reverted from histidine dependence (auxotrophy) to histidine independence (prototrophy) by frameshift mutagens. TA1535 is reverted by base substitution mutagens and TA100 is reverted by mutagens which cause both frameshifts and base substitutions.

The strains of *Salmonella typhimurium* used in this assay were all histidine auxotrophs by virtue of conditionally lethal mutations in their histidine operon. When these histidine-dependent cells (*his-*) were exposed to the test article and grown under selective conditions (the use of minimal media with a trace amount of histidine) only those cells that reverted to histidine independence (*his+*) were able to form colonies. The trace amount of histidine in the media permitted the plated bacteria to undergo a few cell divisions that are essential for the full expression of mutagenesis. The *his+* revertants were readily discernible as colonies against the limited background growth of the *his-* cells.

MATERIALS AND METHODS

The experimental materials, methods, and procedures were based on those described by Ames et al. (1975) and Yahagi et al. (1975).

Media and Reagents

Top Agar for Selection of Histidine Revertants: Minimal top agar was prepared with 0.7% agar (w/v) and 0.5% NaCl (w/v). The agar was sterilized by autoclaving, distributed into sterile bottles, and stored at room temperature prior to use. Immediately before use in the mutagenicity assay, the top agar was melted and supplemented with a sterile solution containing 0.5 mM L-histidine and 0.5 mM D-biotin (10% v/v).

Minimal Bottom Agar: The bottom agar was Vogel-Bonner minimal medium E (Vogel and Bonner, 1956), supplemented with 0.2% (w/v) glucose.

Nutrient Broth: The nutrient broth used for growing overnight cultures of the tester strains was Vogel-Bonner salt solution supplemented with 2.5% (w/v) Oxoid Nutrient Broth No. 2 (dry powder).

13

Exogenous Metabolic Activation

Liver Microsomal Enzymes - S9 Homogenate: The S9 liver homogenate was prepared from male Sprague-Dawley rats that had been injected intraperitoneally (ip) with Aroclor 1254 (500 mg/kg) five days prior to preparation of the homogenate and was purchased from Molecular Toxicology, Inc. The S9 homogenate was characterized for its ability to metabolize selected promutagens to their mutagenic forms in the Ames Test as described by deSerres and Shelby (1979).

S9 Reaction Mixture: A mixture of S9 homogenate and cofactors was prepared immediately before use in those assays that required metabolic activation. One mL of this reaction mixture contained the following components:

H_2O	0.70 mL
1.00M NaH_2PO_4/Na_2HPO_4, pH 7.4	0.10 mL
0.25M Glucose-6-phosphate	0.02 mL
0.10M NADP	0.04 mL
0.2M $MgCl_2/0.825M$ KCl	0.04 mL
S9 Homogenate	0.10 mL

Test System

Tester Strains: The tester strains employed were the *Salmonella typhimurium* histidine auxotrophs TA98, TA100, TA1535, TA1537, and TA1538. Frozen permanent stocks of each tester strain were prepared by growing fresh overnight cultures, adding DMSO (0.09 mL/mL of culture), and freezing 1.5 mL aliquots at ≤ -70°C. The following description of the tester strains that follows is based on that provided by Ames et al. (1975).

In addition to a mutation in the histidine operon discussed in the introduction, all strains contained two additional mutations that enhanced their sensitivity to some mutagenic compounds. The *rfa* wall mutation results in the loss of one of the enzymes responsible for the synthesis of part of the lipopolysaccharide barrier of the bacterial cell wall. The resulting cell wall deficiency increases permeability to certain classes of chemicals such as those containing large ring systems (i.e. benzo(a)pyrene) that would otherwise be excluded by a normal intact cell wall. The second mutation, a deletion of the *uvrB* gene, results in a deficient DNA excision repair system that greatly enhances the sensitivity of these strains to some mutagens. Because the *uvrB* deletion extends through the *bio* gene, all strains containing this deletion also required biotin for growth.

Strains TA98 and TA100 also contained the R-factor plasmid, pKM101, that further increases the sensitivity of these strains to some mutagens. The mechanism by which this plasmid increases sensitivity to mutagens has been suggested to be by modification of an existing bacterial DNA repair polymerase complex involved with the mismatch-repair process.

Master Plates: Master plates of the tester strains were prepared by streaking each strain from a frozen permanent stock onto minimal agar appropriately supplemented with histidine (260 μM), biotin (3 μM), and for strains containing the R-factor, ampicillin (25 μg/mL). Tester strain master plates were stored at 6 ± 4°C.

Preparation of Overnight Cultures: Overnight cultures were prepared by transferring a colony from the appropriate master plate to a flask containing culture medium. In order to assure that cultures were harvested in late log phase, the length of incubation was determined by spectrophotometric

14

monitoring.   Inoculated flasks were placed in a shaker/incubator that was programmed to begin operation (shaking, 125 ± 25 rpm; incubation, 37 ± 2°C) so that the overnight cultures were in log phase or late log phase when turbidity monitoring began.   Cultures were harvested once a predetermined turbidity was reached because overgrowth of cultures can result in loss of sensitivity to some mutagens.

Confirmation of Tester Strain Genotypes: Tester strain cultures were checked for the following genetic markers on the day of their use in the mutagenicity assay:

rfa Wall Mutation: The presence of the *rfa* wall mutation was confirmed by demonstration of sensitivity to crystal violet.   An aliquot of an overnight culture of each strain was overlaid onto plates containing selective media and an antibiotic sensitivity disk containing 10 μg of crystal violet was added.   Sensitivity was demonstrated by inhibition of bacterial growth in a zone immediately surrounding the disk.

pKM101 Plasmid R-factor: The presence of the pKM101 plasmid was confirmed for tester strains TA98 and TA100 by demonstration of resistance to ampicillin.   An aliquot of an overnight culture of each strain was overlaid onto plates containing selective media and an antibiotic sensitivity disk containing 10 μg of ampicillin was added. Resistance was demonstrated by bacterial growth in the zone immediately surrounding the disk.

Characteristic Number of Spontaneous Revertants: The mean number of spontaneous revertants per plate in the vehicle controls that are characteristic of the respective strains was demonstrated by plating 100 μL aliquots of the culture along with the appropriate vehicle on selective media.

Experimental Design

Test Article Characteristics and Handling: PFDA (Lot No. 1105ML, CAS# 335-76-2) was provided by the U.S. Air Force.   The test article consisted of white, crystalline flakes (MP 77-79°C, BP 218°C/740 mm Hg) and was stored at room temperature in its original container.   DMSO was used as the vehicle and the test article formed a solution at a concentration of 200 mg/mL that was the most concentrated stock dilution of test article prepared.   The test article remained in solution at all subsequent dilutions prepared for the mutagenicity assay.

Dose Rangefinding Study: The dose rangefinding study was conducted using tester strain TA100 both in the presence and absence of S9 microsomal enzymes.   TA100 was used because the growth inhibitory effect (cytotoxicity) of the test article on this strain is generally representative of the effect observed on the other tester strains.   In addition, TA100's comparatively high number of spontaneous revertants per plate affords the ability to discern gradations of cytotoxicity from routine experimental variation.   Also, the cytotoxicity induced by a test article in the presence of microsomal enzymes may vary greatly from that observed in the absence of microsomal enzymes. Therefore, this would require that different test article dose ranges be tested in the mutagenicity assay based on the presence or absence of the microsomal enzymes.

15

Ten doses of test article ranging from 10 to 10,000 μg/plate were tested. The assay was conducted using one plate per dose in the presence and absence of S9 microsomal enzymes. Cytotoxicity in this study was detectable as a decrease in the number of revertant colonies per plate and/or a thinning or disappearance of the bacterial background lawn. Routinely, the maximum dose selected to be tested in the mutagenicity assay should demonstrate cytotoxicity.

Mutagenicity Assay: The mutagenicity assay was performed using tester strains TA98, TA100, TA1535, TA1537, and TA1538 and used three plates per dose in the presence and absence of S9 microsomal enzymes. Six doses of the test article ranging from 333 to 10,000 μg/plate were tested in the absence of S9 metabolic activation and six doses ranging from 33.3 to 10,000 μg/mL were tested in the presence of S9 metabolic activation along with the appropriate vehicle and positive controls. The doses tested were selected based on the results of the dose rangefinding study and reflect the fact that the exposure of the test system to the test article does not cease at the end of the 20 min preincubation period. A dose of 10,000 μg/plate indicates that the bacteria are exposed to a concentration of 15,400 μg of test article/mL of preincubation mixture for 20 min prior to being combined with 2 mL of overlay agar and being overlaid onto 25 mL of bottom agar.

Frequency and Route of Administration: The test system was exposed to the test article via the preincubation modification of the Ames Test originally described by Yahagi et al. (1975). This methodology has been shown to detect mutagenicity with certain classes of chemicals, such as nitrosamines or volatile compounds, that may not be detected in the standard plate incorporation method. All doses of test article, vehicle controls, and positive controls were preincubated and plated in triplicate.

Positive Controls: The following compounds were used as the positive controls: 2-aminoanthracene (Sigma Chemical Co., practical grade); 2-nitrofluorene (Aldrich Chemical Co., 98%); sodium azide (Sigma Chemical Co., practical grade; ICR-191 (Polysciences Inc., > 95% pure). All combinations of positive controls and tester strains plated concurrently with the assay are listed below.

POSITIVE CONTROL AND TESTER STRAIN COMBINATIONS

Tester Strain	S9 Mix	Positive Control	Conc. per Plate
TA98	+	2-aminoanthracene	2.5 μg
TA98	−	2-nitrofluorene	1.0 μg
TA100	+	2-aminoanthracene	2.5 μg
TA100	−	sodium azide	2.0 μg
TA1535	+	2-aminoanthracene	2.5 μg
TA1535	−	sodium azide	2.0 μg
TA1537	+	2-aminoanthracene	2.5 μg
TA1537	−	ICR-191	2.0 μg
TA1538	+	2-aminoanthracene	2.5 μg
TA1538	−	2-nitrofluorene	1.0 μg

16

Vehicle Controls: Appropriate vehicle controls were plated for all tester strains both in the presence and absence of S9 microsomal enzymes. The vehicle control was plated, using an aliquot of vehicle equal to the aliquot of test article dilution plated, along with an aliquot of the appropriate tester strain, on selective agar.

Sterility Controls: In order to determine the sterility of the test article, the highest test article dose tested in the mutagenicity assay was checked for sterility by plating an aliquot volume equal to that used in the assay on selective agar. In order to determine the sterility of the S9 mixture and 0.1 M phosphate buffer, a 0.5 mL aliquot was plated on selective agar.

Plating Procedures: The plating procedures employed were similar to those described by Ames et al. (1975) and Yahagi et al. (1975). These procedures were employed for both the dose rangefinding study and the mutagenicity assay. Each plate was labeled with a code system which identified the test article, tester strain, test phase, dose, and activation condition.

The test article was diluted and the S9 mixture was prepared immediately before their use in any experimental procedure. When S9 mix was required, 0.5 mL of S9 mix was added to 13 x 100 mm glass culture tubes, pre-heated to 37 ± 2°C. To these tubes were added 100 μL of appropriate tester strain and 50 μL of vehicle or test article dilution. When S9 mix was not required, 0.5 mL of 0.1M phosphate buffer was substituted for the S9 mixture. After vortexing, the mixture was allowed to incubate for 20 ± 2 min at 37 ± 2°C. Two mL of molten selective top agar were added to each tube and the mixture was vortexed and overlaid onto the surface of 25 mL of minimal bottom agar contained in a 15 x 100 mm petri dish. After the overlay had solidified, the plates were inverted and incubated for 48 ± 8 h at 37 ± 2°C.

Scoring Plates: Plates that were not scored immediately after the 48-h incubation period were held at 6 ± 4°C until scoring could be completed.

The condition of the background bacterial lawn was evaluated for evidence of cytotoxicity caused by the test article by using a dissecting microscope. The cytotoxicity was scored relative to the vehicle control plate and has been noted along with the revertant counts for all plates at that dose on the data tables using the code system presented in Appendix 3-A. In addition to the cytotoxicity, any test article precipitate observed on the plates was also noted at the appropriate dose on the data tables, again using the code system presented in Appendix 3-A.

Revertant colonies for a given tester strain and activation condition were counted either entirely by automated colony counter or entirely by hand. If the plates contained sufficient test article precipitate to interfere with automated colony counting, then they were counted manually.

For all replicate platings, the mean number of revertants per plate was calculated and the standard deviation around the mean was also calculated.

RESULTS AND DISCUSSION

Dose Rangefinding Study

The doses of PFDA for testing in the mutagenicity assay were selected based on the results of the dose rangefinding study conducted on the test article using tester strain TA100. Ten doses of the test article ranging from

17

10 to 10,000 µg per plate were tested and the results are presented in Table 3-1. No cytotoxicity was observed in the presence of S9 as evidenced by a normal background lawn and no decrease in the number of revertants per plate. In the absence of S9, a slight reduction of the bacterial background lawn was observed at doses of 333 µg per plate and above. This lawn reduction was not accompanied by a decrease in the number of revertants per plate.

TABLE 3-1. DOSE RANGEFINDING STUDY FOR PFDA

	TA100 Revertants per plate			
	With S9		Without S9	
µg/Plate	Number of Colonies/Plate	Appearance of Background Lawn*	Number of Colonies/Plate	Appearance of Background Lawn*
0.00 (Vehicle) (50 µL)	109	1	106	1
PFDA				
10.0	83	1	100	1
33.3	116	1	99	1
66.7	105	1	94	1
100	99	1	81	1
333	115	1	109	2
667	117	1	97	2
1000	111	1	93	2
3330	91	1	72	2
6670	91	1	79	2
10000	94	1	83	2

*Background Lawn Evaluation Codes:
1 = normal
2 = slightly reduced
3 = moderately reduced
sp = slight precipitate
mp = moderate precipitate
    (requires hand count)

4 = extremely reduced
5 = absent
6 = obscured by precipitate
hp = heavy precipitate
    (requires hand count)

Mutagenicity Assay

The results of the dose rangefinding study were used to select 6 doses to be tested in the mutagenicity assay. The doses selected ranged from 333 to 10,000 µg per plate in the presence of S9 and from 33.3 to 10,000 µg per plate in the absence of S9. Because lawn toxicity was observed in the absence of S9 in the dose rangefinding assay, a wider dose range was covered in the absence of S9 in the mutagenicity assay.

The mutagenicity assay results for PFDA are presented in Tables 3-2 and 3-3. The data are presented as mean revertants per plate ± standard deviation for each treatment and control group (Table 3-3) and as individual plate counts (Table 3-2). All data were acceptable and no positive increase in the number of histidine revertants per plate was observed either in the presence or absence of S9 microsomal enzymes. All criteria for a valid study were met (See Appendix 3-B).

CONCLUSION

The results of the *Salmonella*/Reverse Mutation assay (Ames Test), Preincubation Method, indicated that under the conditions of this study, PFDA did not cause a positive increase in the number of histidine revertants per plate for any of the tester strains either in the presence or absence of microsomal enzymes prepared from Aroclor-induced rat liver.

TABLE 3-2. INDIVIDUAL PLATE COUNTS FROM AMES TEST OF PFDA

	Dose/Plate		TA98			TA100			TA1535			TA1537			TA1538			Background Lawn[*]
			1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	
MICROSOMES: Rat Liver																		
VEHICLE CONTROL			23	32	20	92	93	119	15	9	13	9	4	7	20	13	23	1
TEST ARTICLE	333 µg		25	29	22	102	101	126	14	2	9	6	11	8	15	12	16	1
	667 µg		23	20	12	108	125	86	11	8	13	8	6	2	12	15	9	1
	1000 µg		20	18	19	85	92	101	14	14	12	14	6	5	19	15	16	1
	3330 µg		23	19	16	114	84	70	10	7	8	5	10	7	10	9	17	1
	6670 µg		11	17	18	68	98	95	10	11	15	4	2	5	13	9	14	2[a]
	10000 µg		20	15	19	96	83	64	7	7	0	8	5	7	10	5	9	2[a]
POSITIVE CONTROL **			1086	980	972	958	894	885	138	102	117	169	159	171	1135	1168	1112	1
MICROSOMES: None																		
VEHICLE CONTROL			16	13	14	71	93	78	15	13	18	4	6	2	13	13	15	1
TEST ARTICLE	33.3 µg		9	13	10	C	104	88	13	10	11	8	3	5	10	9	17	1
	100 µg		17	12	16	81	73	75	14	15	16	5	1	4	16	19	10	1
	333 µg		12	13	12	61	73	73	14	12	8	3	6	6	14	12	11	1
	1000 µg		9	9	10	57	70	67	10	11	16	4	5	6	7	13	11	2
	3330 µg		11	14	16	58	78	77	18	13	12	1	1	4	9	13	9	2
	10000 µg		12	_	8	64	67	75	7	10	8	0	6	5	11	11	7	2
POSITIVE CONTROL ***			234	291	304	719	736	815	691	680	703	1764	1814	1875	449	416	482	1

[a] Bacterial background lawn was evaluated as normal (1) for tester strains TA100 and TA1535 at this dose level.

* Background Lawn Evaluation Codes:

1 = normal	2 = slightly reduced	3 = moderately reduced
4 = extremely reduced	5 = absent	6 = obscured by precipitate
sp = slight precipitate	mp = moderate precipitate	hp = heavy precipitate
	(requires hand count)	(requires hand count)

** TA98	2-aminoanthracene 2.5 µg/plate	*** TA98	2-nitrofluorene	1.0 µg/plate
TA100	2-aminoanthracene 2.5 µg/plate	TA100	sodium azide	2.0 µg/plate
TA1535	2-aminoanthracene 2.5 µg/plate	TA1535	sodium azide	2.0 µg/plate
TA1537	2-aminoanthracene 2.5 µg/plate	TA1537	ICR-191	2.0 µg/plate
TA1538	2-aminoanthracene 2.5 µg/plate	TA1538	2-nitrofluorene	1.0 µg/plate

C = No count due to contamination.

TABLE 3-3. SUMMARY OF TEST RESULTS FOR AMES TEST OF PFDA

| | Dose/Plate | Mean Revertants per Plate with Standard Deviations | | | | | | | | | | Background Lawn[a] |
| | | TA98 | | TA100 | | TA1535 | | TA1537 | | TA1538 | | |
		Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
MICROSOMES: Rat Liver												
VEHICLE CONTROL		25	6	101	15	12	3	7	3	19	5	1
TEST ARTICLE	333 μg	25	4	110	14	8	6	8	3	14	2	1
	667 μg	18	6	106	20	11	3	5	3	12	3	1
	1000 μg	19	1	93	8	13	1	8	5	17	2	1
	3330 μg	19	4	89	22	8	2	7	3	12	4	1
	6670 μg	15	4	87	17	12	3	4	2	12	3	2[a]
	10000 μg	18	3	81	16	5	4	7	2	8	3	2[a]
POSITIVE CONTROL **		1013	64	912	40	119	18	166	6	1138	28	1
MICROSOMES: None												
VEHICLE CONTROL		14	2	81	11	15	3	4	2	14	1	1
TEST ARTICLE	33.3 μg	11	2	96	11	11	2	5	3	12	4	1
	100 μg	15	3	76	4	15	1	3	2	15	5	1
	333 μg	12	1	69	7	11	3	5	2	12	2	1
	1000 μg	9	1	65	7	12	3	5	1	10	3	2
	3330 μg	14	3	71	11	14	3	2	2	10	2	2
	10000 μg	9	3	69	6	8	2	4	3	10	2	2
POSITIVE CONTROL ***		276	37	757	51	691	12	1818	56	449	33	1

[a] Bacterial background lawn was evaluated as normal (1) for tester strains TA100 and TA1535 at this dose level.

* Background Lawn Evaluation Codes:

1 = normal	2 = slightly reduced	3 = moderately reduced
4 = extremely reduced	5 = absent	6 = obscured by precipitate
sp = slight precipitate	mp = moderate precipitate	hp = heavy precipitate
	(requires hand count)	(requires hand count)

**	TA98	2-aminoanthracene 2.5 μg/plate	***	TA98	2-nitrofluorene	1.0 μg/plate
	TA100	2-aminoanthracene 2.5 μg/plate		TA100	sodium azide	2.0 μg/plate
	TA1535	2-aminoanthracene 2.5 μg/plate		TA1535	sodium azide	2.0 μg/plate
	TA1537	2-aminoanthracene 2.5 μg/plate		TA1537	ICR-191	2.0 μg/plate
	TA1538	2-aminoanthracene 2.5 μg/plate		TA1538	2-nitrofluorene	1.0 μg/plate

20

REFERENCES

Ames, B.N., J. McCann, and E. Yamasaki. 1975. Methods for detecting carcinogens and mutagens with the *Salmonella*/Mammalian-microsome mutagenicity test. *Mutation Res.* 31:347-364.

deSerres, F.J. and M.D. Shelby. 1979. Recommendations on data production and analysis using the *Salmonella*/Microsome mutagenicity assay: *Mutation Res.* 64:159-165.

Vogel, H.J. and D.M. Bonner. Acetylornithinase of *E. coli*: Partial purification and some properties. *J. Biol. Chem.* 218:97-106.

Yahagi, T., M. Degawa, Y. Seino, T. Matsushima, M. Nagao, T. Sugimura, and Y. Hashimoto. 1975. Mutagenicity of carcinogenic azo dyes and their derivatives. *Cancer Letters* 1:91-96.

APPENDIX 3-A

BACTERIAL BACKGROUND LAWN EVALUATION CODE

The condition of the background bacterial lawn is evaluated both macroscopically and microscopically (using a dissecting microscope) for indications of cytotoxicity and test article precipitate as follows:

CODE DEFINITION	CHARACTERISTICS OF BACKGROUND LAWN
1 Normal	A healthy microcolony lawn.
2 Slightly Reduced	A noticeable thinning of the microcolony lawn and an increase in the size of the microcolonies compared to the vehicle control plate.
3 Moderately Reduced	A marked thinning of the microcolony lawn and an increase in the size of the microcolonies compared to the vehicle control plate.
4 Extremely Reduced	An extreme thinning of the microcolony lawn and an increase in the size of the microcolonies compared to the vehicle control plate.
5 Absent	A complete lack of any microcolony lawn.
6 Obscured by Precipitate	The background bacterial lawn cannot be accurately evaluated due to microscopic and/or macroscopic test article precipitate.

Evidence of macroscopic test article precipitate on the plates is recorded by addition of the following precipitate code to the code number used to evaluate the condition of the background bacterial lawn.

SP Slight Precipitate	Noticeable macroscopic precipitate on the plate, however, the precipitate does not influence automated counting of the plate.
MP Moderate Precipitate	The amount of macroscopic precipitate on the plate would interfere with automated counting, thus, requiring the plate to be hand counted.
HP Heavy Precipitate	The large amount of macroscopic precipitate on the plate makes the required hand counting difficult.

Example: 4-MP would indicate a plate observed to have an extremely reduced background lawn which had to be counted manually due to the marked amount of macroscopic test article precipitate.

CRITERIA FOR THE DETERMINATION OF A VALID TEST

The following criteria must be met for the assay to be considered valid:

rfa Wall Mutation: In order to demonstrate the presence of the deep rough mutation, all tester strain cultures must exhibit sensitivity to crystal violet.

pKM101 Plasmid R-Factor: In order to demonstrate the presence of the pKM101 Plasmid R-factor, all tester strains must exhibit resistance to ampicillin.

Characteristic Number of Spontaneous Revertants: All tester strain cultures must exhibit a characteristic number of spontaneous revertants per plate in the vehicle controls. The acceptable ranges are as follows:

TA98	8 - 60
TA100	60 - 240
TA1535	4 - 45
TA1537	2 - 25
TA1538	3 - 35

Tester Strain Culture Density: In order to ensure that appropriate numbers of bacteria are plated, tester strain culture density must be greater than or equal to 5.0×10^8 bacteria per mL and/or have reached a target level of turbidity demonstrated to produce cultures with a density greater than or equal to 5.0×10^8.

Positive Control Values: All positive controls must exhibit at least a 3-fold increase in the number of revertants per plate over the mean value for the vehicle control for the respective strain.

Cytotoxicity: A minimum of three non-toxic doses are required to evaluate assay data.

Evaluation of Test Results

Tester Strains TA98 and TA100: For a test article to be considered positive, it must cause at least a 2-fold increase in the mean revertants per plate of at least one tester strain over the mean vehicle control value for that tester strain. This increase in the mean number of revertants per plate must be accompanied by a dose response to increasing concentrations of the test article.

Tester Strains TA1535, TA1537, and TA1538: For a test article to be considered positive, it must cause at least a 3-fold increase in the mean revertants per plate of at least one tester strain over the mean vehicle control value for that tester strain. This increase in the mean number of revertants per plate must be accompanied by a dose response to increasing concentrations of the test article.

SECTION 4

MUTAGENICITY TEST ON PFDA IN THE CHO/HGPRT FORWARD MUTATION ASSAY

R.R. Young

ABSTRACT

The objective of this assay was to evaluate the ability of PFDA to induce forward mutations at the HGPRT locus in CHO cells under conditions with and without metabolic activation by S9 microsomal enzymes.

PFDA was soluble in DMSO at a concentration of 100.0 mg/ml and was used to prepare primary 100X stocks for use in the assay procedures. Treatment media were prepared by making 1:100 dilutions of the primary stocks into F12 tissue culture medium. Glass pipets, tubes, and culture vessels were used for test article preparation and treatment due to potential reactivity of the test article with plastic. Preliminary cytotoxicity testing showed the test material to be toxic to CHO cells both with and without S9 metabolic activation with total, or near total, cell killing occurring at a concentration of 0.25 mg/mL in the absence of metabolic activation and at 0.5 mg/mL with S9 metabolic activation.

Mutation assays were performed both with and without S9 metabolic activation. Eight test article concentrations ranging from 0.01 to 0.3 mg/mL were tested in the absence of S9 enzymes. Eight test article concentrations ranging from 0.005 to 0.5 mg/mL were also tested in the presence of S9 activation. The test article produced toxicity in both mutation assays. The mutant frequency of treated cultures varied within the range acceptable for background mutant frequencies (0 to 16.8×10^{-6}). Two cultures from those tested without S9 enzymes and one culture from those exposed to S9 enzymes had a mutant frequency that was statistically elevated over the mutant frequencies of the concurrent vehicle control cultures. These elevated mutant frequencies were within the range considered acceptable for background mutant frequencies and were consistent with normal assay variation.

Because the culture with a mutant frequency that was significantly elevated was the highest dosed culture that survived, and because the mutant frequency was at the high end of the normal background range, a repeat activation mutation assay was performed. The second activation mutation assay employed six doses ranging from 0.01 to 0.2 mg/mL. While the mutant frequency of treated cultures was within the normal background range, two cultures had a significantly elevated mutant frequency. The results did not show a dose-related increase in mutant frequency and were consistent with normal assay variation. Therefore, PFDA was considered negative for inducing forward mutations at the HGPRT locus in CHO cells under the S9 metabolic activation and nonactivation conditions of testing.

INTRODUCTION

HGPRT is a cellular enzyme that permits cells to salvage hypoxanthine and guanine for use in DNA synthesis. The HGPRT enzyme utilizes the substrates 5-phosphoribosyl-1-pyrophosphate, hypoxanthine, or guanine to catalyze the formation of inosine or guanosine monophosphate. If a purine analog such as 6-thioguanine (TG) is included in the growth medium, the analog will be phosphorylated via the HGPRT pathway and incorporated into nucleic acids, eventually resulting in cellular death. The HGPRT locus is located on the X chromosome and because only one of the two X chromosomes is functional in the CHO cells, a single-step forward mutation from HGPRT+ to HGPRT- in the functional X chromosome renders the cell unable to utilize hypoxanthine, guanine, or TG supplied in the culture medium. These mutants are as viable as

24

wild-type cells in normal medium because DNA synthesis may still proceed by *de novo* synthetic pathways that do not involve hypoxanthine or guanine as intermediates. The basis for the selection of HGPRT- mutants is the loss of their ability to utilize toxic purine analogs (e.g., TG), that enables only the HGPRT- mutants to grow in the presence of TG. Cells that grow to form colonies in the presence of TG are assumed to have mutated, either spontaneously or by the action of the test article, to the HGPRT- genotype.

MATERIALS AND METHODS

Test Material

PFDA was identified as Lot No. 1105ML and was obtained from the U.S. Air Force. The white crystals was stored at room temperature in the dark.

Media

The cells used during experimental studies were maintained in Ham's Nutrient Mixture F12 supplemented with L-glutamine, antibiotics, and fetal bovine serum (FBS, 8% v/v), hereafter referred to as culture medium. Cleansing medium used for reducing the spontaneous frequency of HGPRT- mutants prior to experimental studies consisted of culture medium supplemented with 5.0×10^{-6} M thymidine, 1.0×10^{-5} M hypoxanthine, 1.0×10^{-4} M glycine, 3.2×10^{-6} M of either aminopterin or methotrexate, and the concentration of FBS was reduced to 5% by volume. Recovery medium was similar to cleansing medium except that the aminopterin or methotrexate component was removed and the FBS was increased to 8% by volume. Selection medium for mutants was hypoxanthine-free F12 medium containing 4 μg/mL (24 mM) of TG and the FBS component reduced to 5% by volume.

Indicator Cells

The indicator cells used for this study were CHO cells originally derived from the ovary of a female Chinese hamster (Kao and Puck, 1968). Characteristics of the cell line are high clonability (approximately 85%) and rapid doubling time (11-14 h). The particular subclone used in this assay was CHO-K1-BH$_4$ that has been demonstrated to be sensitive to many chemical mutagens. Master stocks of the cells were maintained frozen in liquid nitrogen.

Laboratory cultures were maintained as monolayers at 37 ± 1.5°C in a humidified atmosphere containing 5 ± 1.5% CO$_2$ and were periodically checked for karyotype stability and for the absence of *Mycoplasma* contamination. To reduce the negative control frequency (spontaneous frequency) of HGPRT- mutants to the minimum possible, the cell cultures were exposed to conditions that selected against the HGPRT- phenotype. Cells were maintained in cleansing medium for two to three days, placed in recovery medium for one day, and then returned to culture medium. Cleansed cultures were used to initiate mutation assays from three to seven days after having been removed from cleansing medium.

Control Articles

A single negative (media) control culture was prepared for each portion of the rangefinding cytotoxicity assay by carrying cells unexposed to the test article through all of the assay operations. Negative controls were not prepared for the mutagenicity assays.

Vehicle controls were prepared for each portion of the assay by exposing cells to 1% DMSO in culture medium for 4 h. Single vehicle control cultures were used in the rangefinding cytotoxicity assay and duplicate vehicle controls were used in the mutagenicity assay.

5-Bromo-2'-deoxyuridine (BrdU) is highly and reproducibly mutagenic to CHO-K1-BH$_4$ cells without S9 metabolic activation. BrdU (Sigma Chemical Co.) was used at a concentration of 50 μg/mL of culture medium as a positive control article for mutagenicity assays conducted without S9 metabolic activation. 3-Methylcholanthrene (MCA, Sigma Chemical Co.) requires metabolic activation by microsomal enzymes to become mutagenic to CHO-K1-BH$_4$ cells and was used at a concentration 5 μg/mL of culture medium as a positive control article for mutagenicity assays performed with S9 activation.

S9 Metabolic Activation System

The metabolic activation system was composed of rat liver enzymes and an energy producing reaction mixture prepared in a phosphate buffer (pH 7.8). The enzymes were contained in a 9000 x g supernatant (S9 fraction) from liver homogenate prepared from Sprague-Dawley rats treated with 500 mg/kg of Aroclor 1254 five days prior to sacrifice and purchased from Molecular Toxicology, Inc. The S9 fraction and reaction mixtures were retained frozen at about -80°C until used. These components were thawed immediately before use and combined to form the metabolic activation system described below.

Activation System Component	Final Concentration in Cultures
NADP (sodium salt)	1.0 mM
Glucose-6-phosphate	5.0 mM
Calcium chloride	2.0 mM
Potassium chloride	6.6 mM
Magnesium chloride	2.0 mM
Phosphate	2.0 mM
S9 homogenate	15.0 - 20.0 μL/mL

The amount of S9 homogenate per culture was dependent upon the lot of S9 in use at any time. Before use each lot of S9 homogenate was tested in culture at various concentrations using chemicals such as benzo(a)pyrene or MCA. The optimum S9 concentration was selected based on induction of HGPRT-mutants in CHO cells exposed to these chemicals in culture, and this amount of S9 was used in all subsequent assays with that particular lot of S9.

Dosing Procedure

PFDA was dissolved in DMSO at a concentration of 100 mg/mL which was 100 times the highest desired treatment concentration. Primary 100X test material stock solutions at lower concentrations were prepared by serial dilution with DMSO. Final 1X dosing solutions were prepared by making 1:100 dilutions of the primary stocks into culture medium containing 8% FBS for nonactivation studies and 5% FBS for activation studies. The volume of culture medium diluent in the activation studies was reduced to compensate for the volume of S9 reaction mixture used.

26

Preparations of test material in the vehicle were made fresh each day. Treatments were initiated by replacing the culture medium on the cell cultures with the treatment medium containing the test material at the desired concentrations.

Rangefinding Cytotoxicity Testing

A wide range of test article concentrations was tested for cytotoxicity both with and without S9 metabolic activation. Ten concentrations that ranged from 0.00195 to 1.0 mg/mL were used. In addition, one negative (media) control and one vehicle control containing 1% DMSO were used in each cytotoxicity assay.

The cells were quantitatively seeded at 200 cells per glass flask, allowed to attach overnight (16 to 18 h), and exposed to the test or control article for 4 h at $37 \pm 1.5°C$ in a humidified atmosphere containing 5% CO_2. The cells were then washed twice with Dulbecco's phosphate buffered saline (PBS) and incubated in F12 culture medium for six additional days to permit time for colony development. Colonies were then fixed in alcohol, stained with Giemsa, and counted by eye, excluding those colonies with approximately 50 cells or less. Cytotoxicity was expressed as a percentage of colony counts in treated cultures versus control cultures. The preliminary cytotoxicity information was used to select doses for the mutation assay.

Nonactivation Mutagenicity Assay

This procedure was based on that reported by Hsie et al. (1975), reviewed by Hsie et al. (1981), with modifications suggested by Myhr and DiPaolo (1978). The cleansed cells were plated at approximately 2.4×10^6 cells per 75 cm^2 glass flask on the day before dosing. The time between plating and treatment was about 18 h. At that time cell cultures were treated with test or control material for 4 h at $37 \pm 1.5°C$ in a humidified atmosphere with 5% CO_2. After treatment, the cell monolayers were washed twice with PBS, trypsinized, and suspended in culture medium. The cell suspension from cultures exposed to each dose was counted using a Coulter Counter and replated at 1.5×10^6 cells into each of two 150-mm dishes and at 200 cells into each of three 60-mm dishes. The small dishes were incubated for seven days to permit colony development and the determination of the cytotoxicity associated with each treatment. The larger dishes were incubated for seven days (the expression period) to permit growth and expression of induced mutations. The mass cultures were subcultured every two or three days during the expression period to maintain logarithmic cell growth. At each subculture the cells from the two 150-mm dishes from each dose level were combined and reseeded at about 1.5×10^6 cells into each of two 150-mm dishes.

At the end of the expression period, each culture was reseeded at 2×10^5 cells per 100-mm dish (12 dishes total) in mutant selection medium. Three 60-mm dishes were seeded at 200 cells each in culture medium to determine the cloning efficiency (CE) of each culture. After incubation for seven to ten days at $37 \pm 1.5°C$ in a humidified atmosphere with 5% CO_2, the colonies were fixed with alcohol, stained with Giemsa, and counted to determine the number of TG-resistant colonies in mutant selection dishes and the number of colonies in the CE dishes. The colonies were counted by eye, excluding those with approximately 50 cells or less.

27

Activation Mutagenicity Assay

The activation assay was performed independently with its own set of vehicle and positive controls. The procedure was identical to the nonactivation assay except for the addition of the S9 fraction of rat liver homogenate and necessary cofactors during the 4-h treatment period. The FBS content of the medium used for dosing was reduced to 5% by volume.

Data Presentation

The raw data were used to calculate several assay parameters. The chosen combination of raw data and calculated data affords a complete description of events for each treatment condition. The significance of each calculated parameter and its method of calculation are listed below.

Relative Survival to Treatment: This parameter gives the clonal cytotoxicity of each treatment by showing what percentage of the cells were able to form colonies after the treatment period in both the rangefinding cytotoxicity assay and the mutagenicity assay relative to the concurrent vehicle controls. The average number of colonies in three dishes (seeded at 200 cells each) was determined for each treatment condition.

$$\text{Relative Survival (\%)} = \frac{\text{Average no. of colonies per treated culture}}{\text{Average no. of colonies per vehicle control dish}} \times 100\%$$

Relative Population Growth: This parameter shows the cumulative growth of the treated cell population, relative to the vehicle control growth, over the entire expression period and prior to mutant selection. In general, highly toxic treatments will reduce the growth rate as well as the survival.

Values less than 100% indicate growth inhibition. For example, 50% and 25% relative growth values would indicate treated cell populations that were one and two population doublings behind the vehicle control cultures. Treated populations that are more than 2 or 3 doublings behind the control might not achieve maximum expression of the TG-resistant phenotype. The relative population growth is calculated from cell count data not presented in this report and is intended to provide only an approximate indication of growth during the expression period, since cells are easily lost or not completely released by trypsin during the subculture procedures.

$$\text{Relative Population Growth (\%)} = \frac{\text{Treated culture population increase over the expression period}}{\text{Vehicle control population increase over the expression period}} \times 100\%$$

Absolute Cloning Efficiency: The ability of the cells to form colonies at the time of mutant selection is measured by the absolute CE. This parameter is used as the best estimate of the CE of the mutant cells in the selection dishes. Thus, the observed number of mutant colonies can be converted to the frequency of mutant cells in the treated population.

$$\text{Absolute CE (\%)} = \frac{\text{Average no. of viable colonies per dish}}{200} \times 100\%$$

28

Mutant Frequency: The mutant frequency is the endpoint of the assay. It is calculated as the ratio of colonies found in thioguanine selection medium to the total number of cells seeded, adjusted by the absolute CE. The frequency is expressed in units of 10^{-6}, e.g., the number of mutants per one million cells.

$$\text{Mutant Frequency (\%)} = \frac{\text{Total mutant clones}}{\text{no. of dishes} \times 2 \times 10^5 \times \text{absolute CE}} \times 100\%$$

RESULTS AND DISCUSSION

Test Article Handling

Solubility testing of PFDA with DMSO revealed that good solubility was maintained at a concentration of 100 mg/mL. Dilutions were made with DMSO to prepare a series of 100X primary stocks at lower concentrations. Glass pipets and tubes were used to prepare primary test article stock solutions in DMSO.

Treatment media were prepared by making 1:100 dilutions of the test material stocks into F12 culture medium that contained 8% FBS for the nonactivation studies and 5% FBS for the S9 metabolic activation studies. Fresh primary test material stocks were prepared for each experiment. The cells were treated by replacing the media on the cultures with treatment media containing the different concentrations of test or control media.

The test article remained in solution in culture medium at concentrations ranging from 0.00195 to 1.0 mg/mL. Based upon the color of the culture medium pH indicator, the test article did not appear to alter the pH of the treatment medium at any concentration.

Rangefinding Cytotoxicity Assay

PFDA was tested in the preliminary rangefinding cytotoxicity assay with and without S9 metabolic activation. Ten test article concentrations were used in each case ranging from 0.00195 to 1.0 mg/mL.

The rangefinding cytotoxicity assay revealed that PFDA was toxic to CHO cells in cultures both with and without S9 metabolic activation (Tables 4-1 and 4-2). The test article was nontoxic up to a concentration of 0.125 mg/mL without activation followed by total, or near-total, cell killing at concentrations of 0.25 mg/mL and higher. With the addition of S9 enzymes, increasing toxicity was observed at a concentration of 0.0625 mg/mL and higher with complete cell killing occurring at a concentration of 0.5 mg/mL and above. Results of the cytotoxicity assays were used to select test article concentrations for use in the mutagenicity assay.

Mutagenicity Assay Without Metabolic Activation

Eight test article concentrations were used ranging from 0.01 to 0.3 mg/mL. The test article was toxic to CHO cells at a concentration of 0.2 mg/mL and higher as measured by relative clonal survival (Table 4-3). Four cultures exposed to the test article survived treatment and were available for analysis. In the absence of S9 activation, the mutant frequency of cultures treated with the test material varied randomly with dose within the range considered acceptable for vehicle control mutant frequency variation (0 to 16.8×10^{-6}. Two of the four surviving cultures had a mutant frequency that was significantly elevated over the mutant frequencies of the vehicle control cultures, but the frequency of each culture was within the range

29

TABLE 4-1. CLONAL CYTOTOXICITY ASSAY OF PFDA
WITHOUT METABOLIC ACTIVATION

Sample	Applied Concentration mg/mL	Number Colonies/Dish	Relative Survival[a] (%)	Cloning Efficiency (%)
NC[b]	-----	196	98.5	
VC, 1%[c]	-----	199	100.0	99.5
PFDA	0.00195	199	100.0	
PFDA	0.00391	183	92.0	
PFDA	0.00781	169	84.9	
PFDA	0.0156	202	101.5	
PFDA	0.0313	211	106.0	
PFDA	0.0625	195	98.0	
PFDA	0.125	176	88.4	
PFDA	0.25	4	2.0	
PFDA	0.5	0	0.0	
PFDA	1.0	0	0.0	

[a] Relative to 1% VC for all treatments.
[b] NC = Negative Control, F12 Medium.
[c] VC = Vehicle Control 1% DMSO.

TABLE 4-2. CLONAL CYTOTOXICITY ASSAY OF PFDA
WITH METABOLIC ACTIVATION

Sample	Applied Concentration mg/mL	Number Colonies/Dish	Relative Survival[a] (%)	Cloning Efficiency (%)
NC[b]	-----	169	93.4	
VC, 1%[c]	-----	181	100.0	90.5
PFDA	0.00195	149	82.3	
PFDA	0.00391	176	97.2	
PFDA	0.00781	148	81.8	
PFDA	0.0156	120	66.3	
PFDA	0.0313	155	85.6	
PFDA	0.0625	107	59.1	
PFDA	0.125	100	55.2	
PFDA	0.25	33	18.2	
PFDA	0.5	0	0.0	
PFDA	1.0	0	0.0	

[a] Relative to 1% VC for all treatments.
[b] NC = Negative Control, F12 Medium.
[c] VC = Vehicle Control 1% DMSO.

considered acceptable for background mutant frequencies and was consistent with normal assay variation. Therefore, PFDA was evaluated as negative for inducing forward mutations at the HGPRT locus in CHO cells in the absence of S9 metabolic activation under the conditions of testing.

The positive control treatments with 50 μg/mL BrdU induced a large, significant (p $\leq$ 0.01) increase in mutant frequency. The mutant frequencies of the two vehicle controls were acceptable. Historical control mutant frequency data are presented in Appendix 4-A. The assay results achieved all assay acceptance criteria (Appendix 4B), which provided confidence in the assumption that the recorded data represented a typical response of the test material in the nonactivation assay system.

TABLE 4-3. MUTATION ASSAY OF PFDA WITHOUT METABOLIC ACTIVATION

Nonactivation Test Condition	Survival To Treatment (% Vehicle Control)	Relative Population Growth (% of Control)	Total Mutant Colonies	Absolute CE $\pm$ SD (%)	Mutant Freq in 10^{-6} Units[a]
Vehicle Control[b]	98.0	108.8	9	90.9 $\pm$ 7.3	4.1
Vehicle Control	102.0	91.2	9	91.5 $\pm$ 1.3	4.1
Positive Control[c]	69.7	41.1	237	97.7 $\pm$ 5.4	101.1[d]
Positive Control	61.6	43.7	299	91.7 $\pm$ 7.7	135.9[d]
PFDA (mg/mL)					
0.01	99.4	89.0	10	88.9 $\pm$ 9.3	4.7
0.1	93.6	87.1	21	96.7 $\pm$ 9.1	9.0[e]
0.13	70.7	60.2	24	92.4 $\pm$ 5.1	10.8[f]
0.16	9.3	3.8	11	82.5 $\pm$ 8.3	5.6
0.2	0.0	NS[g]	-	- -	-
0.23	0.0	NS	-	- -	-
0.26	0.0	NS	-	- -	-
0.3	0.0	NS	-	- -	-

[a] Mutant Frequency = Total mutant colonies/No. of dishes x 2 x 10^5 x absolute CE.

[b] Vehicle Control = 1% DMSO.

[c] Positive Control = 50 μg/mL BrdU.

[d] Significant increase: Kastenbaum-Bowman test p $\leq$ 0.01 and mutant frequency $\geq$ 15 x 10^{-6}.

[e] Kastenbaum Bowman test p $\leq$ 0.05 but mutant frequency is within acceptable background range (< 15.0 x 10^{-6}).

[f] Kastenbaum Bowman test p $\leq$ 0.01 but mutant frequency is within acceptable background range (< 15.0 x 10^{-6}).

[g] NS = Not selected due to toxicity.

Mutagenicity Assay With Metabolic Activation

PFDA was tested in the presence of S9 metabolic activation using eight test article concentrations ranging from 0.005 to 0.5 mg/mL. The test article was toxic to CHO cells at concentrations of 0.2 mg/mL and higher as measured by relative clonal survival (Table 4-4). The four remaining treated cultures were plated for mutant selection and were available for analysis. The mutant frequency of cultures treated with the test material varied within the acceptable range of vehicle control mutant frequency variation which is 0 to 10 x 10^{-6} (See Appendix 4-A). One of the four surviving cultures had a mutant

frequency that was significantly elevated over the mutant frequencies of the vehicle control cultures. The mutant frequency of that culture was at the high end of the acceptable range for background mutant frequency variation.

TABLE 4-4. MUTATION ASSAY OF PFDA WITH METABOLIC ACTIVATION
TRIAL 1

Nonactivation Test Condition	Survival To Treatment (% Vehicle Control)	Relative Population Growth (% of Control)	Total Mutant Colonies	Absolute CE ± SD (%)	Mutant Freq in 10^{-6} Units[a]
Vehicle Control[b]	106.8	103.0	15	95.4 ± 5.6	6.6
Vehicle Control	93.2	97.0	14	103.2 ± 1.9	5.7
Positive Control[c]	136.5	144.8	432	100.5 ± 1.8	179.1[d]
Positive Control	152.1	128.7	428	104.0 ± 4.8	171.5[d]
PFDA (mg/mL)					
0.005	94.6	95.5	15	93.4 ± 1.5	6.7
0.01	88.9	106.9	8	93.2 ± 3.6	3.6
0.05	89.6	107.1	6	102.4 ± 4.9	2.4
0.1	65.0	85.6	34	107.2 ± 3.0	14.4[e]
0.2	0.8	NS[f]	-	- -	-
0.3	0.2	NS	-	- -	-
0.4	0.0	NS	-	- -	-
0.5	0.0	NS	-	- -	-

[a] Mutant Frequency = Total mutant colonies/No. of dishes x 2 x 10^5 x absolute CE.

[b] Vehicle Control = 1% DMSO.

[c] Positive Control = 5.0 μg/mL MCA.

[d] Significant increase: Kastenbaum-Bowman test p ≤ 0.01 and mutant frequency ≥ 15 x 10^{-6}.

[e] Kastenbaum Bowman test p ≤ 0.01 but mutant frequency is within acceptable background range (< 15 x 10^{-6}).

[f] NS = Not selected due to toxicity.

A second S9 metabolic activation mutagenicity assay was conducted with doses chosen to cover the region of increasing toxicity obtained in the first trial. Six doses were used ranging from 0.01 to 0.2 mg/mL. In the second activation trial the test article was toxic to CHO cells at concentrations of 0.2 mg/mL and higher as measured by relative clonal survival (Table 4-5). Two of the five surviving cultures had a mutant frequency that was significantly elevated over the mutant frequencies of the vehicle control cultures but were clearly less than 15 x 10^{-6}. The results did not show a dose-related increase in mutant frequency and were consistent with normal assay variation. Therefore, PFDA was evaluated as negative for inducing forward mutations at the HGPRT locus in CHO cells in the presence of S9 metabolic activation under the conditions of testing.

The positive control treatments with 5 μg/mL MCA induced large, significant (p ≤ 0.01) increase in mutant frequency which demonstrated the effectiveness of the S9 metabolic activation system and the ability of the test system to detect known mutagens. The mutant frequencies of the vehicle controls were within the acceptable range (Appendix 4-A). The assay results achieved all assay acceptance criteria (Appendix 4-B) and provided confidence in the assumption that the recorded data represented typical responses of the test material in the assay system.

TABLE 4-5. MUTATION ASSAY OF PFDA WITH METABOLIC ACTIVATION TRIAL II

Nonactivation Test Condition	Survival To Treatment (% Vehicle Control)	Relative Population Growth (% of Control)	Total Mutant Colonies	Absolute CE ± SD (%)	Mutant Freq in 10^{-6} Units[a]
Vehicle Control[b]	101.1	107.2	11	109.5 ± 7.8	4.2
Vehicle Control	98.9	92.8	6	100.2 ± 3.6	2.5
Positive Control[c]	171.3	211.6	445	105.5 ± 15.7	175.8[d]
PFDA (mg/mL)					
0.01	116.8	92.2	11	104.7 ± 9.8	4.4
0.05	97.5	78.9	13	110.3 ± 12.0	4.9
0.1	79.6	51.2	29	113.0 ± 4.4	10.7[e]
0.13	63.6	33.6	19	107.2 ± 11.1	7.4[f]
0.16	18.4	9.3	5	84.4 ± 4.9	2.5
0.2	0.9	T[g]	-	-	-

[a] Mutant Frequency = Total mutant colonies/No. of dishes x 2 x 10^5 x absolute CE.

[b] Vehicle Control = 1% DMSO.

[c] Positive Control = 5.0 μg/mL MCA.

[d] Significant increase: Kastenbaum-Bowman test $p \leq 0.01$ and mutant frequency ≥ 15 x 10^{-6}.

[e] Kastenbaum Bowman test $p \leq 0.01$ but mutant frequency is within acceptable background range (< 15 x 10^{-6}).

[f] Kastenbaum Bowman test $p \leq 0.05$ but mutant frequency is within acceptable background range (< 15 x 10^{-6}).

[g] T = Terminated due to excessive toxicity.

CONCLUSION

The test material, PFDA, was considered negative for inducing forward mutations at the HGPRT locus in CHO cells under both the S9 metabolic activation and nonactivation conditions of the assay.

REFERENCES

Hsie, A.W., P.A. Brimer, T.J. Mitchell, and D.G. Gosslee. 1975. Dose-response relationship for ethyl methanesulfonate-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells. Somat. Cell Genet. 1:247-261.

Hsie, A.W., D.A. Casciano, D.B. Couch, D.F. Krahn, J.P. O'Neil, and B.L. Whitfield. 1981. The use of Chinese hamster ovary cells to quantify specific locus mutation and to determine mutagenicity of chemicals. Mutation Res. 86:193-214.

Kao, F.T. and T.T. Puck. 1968. Genetics of somatic mammalian cells, VII. Induction and isolation of nutritional mutants in Chinese hamster cells. Proc. Natl. Acad. Sci. U.S. 60:1275-1281.

Kastenbaum, M.A. and K.O. Bowman. 1970. Tables for determining the statistical significance of mutation frequencies. Mutation Res. 9:527-549.

Myhr, B.C. and J.A. DiPaolo. 1978. Mutagenesis of Chinese hamster cells in vitro by combination treatments with methyl methanesulfonate and N-acetoxy-2-acetylaminofluorene. Cancer Res. 38:2539-2543.

HISTORICAL CHO HGPRT ASSAY CONTROL MUTANT FREQUENCY DATA

A.   Nonactivation Studies

1.   Pooled negative and solvent controls

Mean (± SD)	$3.9 \pm 2.9 \times 10^{-6}$
Range	0 to 16.8×10^{-6}
Number of experiments	50
Number of controls	88

2.   Positive controls (50 μg/mL 5-bromo-2'-deoxyuridine)

Mean (± SD)	$121.6 \pm 27.9 \times 10^{-6}$
Range	38.7 to 165.6×10^{-6}
Number of experiments	50
Number of controls	59

B.   Activation Studies

1.   Pooled negative and solvent controls

Mean (± SD)	$2.9 \pm 2.1 \times 10^{-6}$
Range	0 to 10.0×10^{-6}
Number of experiments	50
Number of controls	86

2.   Positive controls (5 μg/mL 3-methylcholanthrene)

Mean (± SD)	$370.0 \pm 173.3 \times 10^{-6}$
Range	152.3 to 941.6×10^{-6}
Number of experiments	50
Number of controls	61

The historical control data was compiled from the most recent fifty experiments. Because some experiments contained duplicate controls, the number of independent control cultures exceeded the number of experiments.

APPENDIX 4-B

ASSAY ACCEPTANCE AND EVALUATION CRITERIA

Assay acceptance criteria

An assay normally is considered acceptable for evaluation of the results only if all of the following criteria are satisfied. The activation and nonactivation portions of the mutation assay may be performed concurrently, but each portion is, in fact, an independent assay with its own positive and vehicle controls. The activation or nonactivation assays will be repeated independently, as needed, to satisfy the acceptance and evaluation criteria.

The average absolute cloning efficiency of the vehicle controls should be between 70% and 115%. A value greater than 100% is possible because of errors in cell counts (usually ± 10%) and dilutions during cloning. Cloning efficiencies below 70% do not necessarily indicate substandard culture conditions or unhealthy cells. Assay variables can lead to artificially low cloning efficiencies in the range of 50 to 70% and still yield internally consistent and valid results. Assays with cloning efficiencies in this range will be conditionally acceptable and dependent on scientific judgment. All assays below 50% cloning efficiency will be unacceptable.

The background mutant frequency (average of the vehicle controls) is calculated separately for the activation and nonactivation assays, even though the same population of cells may be used for concurrent assays. The activation vehicle controls contain the S9 activation mix and may have a slightly different mutant frequency than the nonactivation vehicle controls. For both conditions, background frequencies for assays performed with different cell stocks are generally 0 to 10 x 10^{-6}. Assays with backgrounds greater than 15 x 10^{-6} will not be used for evaluation of a test article.

A positive control is included with each assay to provide confidence in the procedures used to detect mutagenic activity. An assay will be acceptable in the absence of a positive control (loss due to contamination or technical error) only if the test article clearly shows mutagenic activity as described in the evaluation criteria. If the test article appears to have no or only weak mutagenic activity, an acceptable assay must have a positive control mutant frequency that is significantly elevated over the concurrent vehicle controls (p ≤ 0.01).

For test articles with little or no mutagenic activity, an acceptable assay should include applied concentrations that reduce the clonal survival to approximately 10% to 15% of the average of the vehicle controls, reach the maximum applied concentrations given in the evaluation criteria, reach a concentration that is approximately twice the solubility limit of the test article in culture medium, or include a high concentration that is at least 75% of an excessively toxic concentration. There is no maximum toxicity requirement for test articles which clearly show mutagenic activity.

Mutant frequencies are normally derived from sets of twelve dishes for the mutant colony count and three dishes for the viable colony count. To allow for contamination losses, an acceptable mutant frequency for treated cultures can be calculated from a minimum of eight mutant selection dishes and two cloning efficiency dishes.

The mutant frequencies for five treated cultures are normally determined in each assay. A required number of different concentrations cannot be explicitly stated, although a minimum of three analyzed cultures is considered necessary under the most favorable test conditions in order to accept a single assay for evaluation of the test article.

35

Assay evaluation criteria

Mutation assays are initiated by exposing cell cultures to about six to eight concentrations of test article that are expected, on the basis of preliminary toxicity studies, to span a range of cellular responses from no observed toxicity to about 10% survival. Five dose levels are usually then selected for completion of the mutation assay. These doses should cover a range of toxicities with emphasis placed on the most toxic doses. An assay may need to be repeated with different concentrations to properly evaluate a test article.

The statistical tables provided by Kastenbaum and Bowman (1970) are used to determine whether the results at each dose level are significantly different from the negative controls at 95% or 99% confidence levels. This test compares variables distributed according to Poissonian expectations by summing up the probabilities in the tails of two binomial distributions. The 95% confidence level must be met as one criterion for considering the test article to be active at a particular dose level. In addition, the mutant frequency must meet or exceed 15×10^{-6} in order to compensate for random fluctuations in the 0 to 10×10^{-6} background mutant frequencies that are typical for this assay.

Observation of a mutant frequency that meets the minimum criteria for a positive response in a single treated culture within a range of assayed concentrations is not sufficient evidence to evaluate a test article as a mutagen. The following test results must be obtained to reach this conclusion for either activation or nonactivation conditions:

A dose-related or toxicity-related increase in mutant frequency should be observed. It is desirable to obtain this relation for at least three doses. However, this depends on the concentration steps chosen for the assay and the toxicity at which mutagenic activity appears. If an increase in mutant frequency is observed for a single dose near the highest testable toxicity, as defined previously, and the number of mutant colonies is more than twice the value needed to indicate a significant response, the test article generally will be considered mutagenic. Smaller increases at a single dose near the highest testable toxicity will require confirmation by a repeat assay.

For some test articles, the correlation between toxicity and applied concentration is poor. The proportion of the applied article that effectively interacts with the cells to cause genetic alterations is not always repeatable or readily controlled. Conversely, measurable changes in the frequency of induced mutants may occur with concentration changes that cause only small changes in observable toxicity. Therefore, either parameter, applied concentration or toxicity (percent survival), can be used to establish whether the mutagenic activity is related to an increase in effective treatment.

Treatments that reduce relative clonal survival to less than five percent may be included in the assay but will not be used as sufficient evidence for mutagenicity as it relates to risk assessment.

A test article is evaluated as nonmutagenic in a single assay only if the minimum increase in mutant frequency is not observed for a range of applied concentrations that extends to concentrations causing about 10% to 15% survival or extends to a concentration at least 75% of that causing excessive toxicity. If the test article is relatively nontoxic, the maximum applied concentration will normally be 5 mg/mL (or 5 µL/mL) for water-soluble

36

materials or 1 mg/mL (or 1 μL/mL) for materials in organic solvents. If a repeat assay does not confirm an earlier, minimal response as discussed above, the test article is evaluated as nonmutagenic in this assay system.

This presentation may not encompass all test situations, and criteria may be used to arrive at a conclusion, especially when data from several repeat assays are available. The interpretation of the results in the Results and Discussion section provides the reasoning involved when departures from the above descriptions occur.

MUTAGENICITY TEST ON PFDA IN AN *IN VITRO* CYTOGENETIC ASSAY MEASURING SISTER CHROMATID EXCHANGE AND CHROMOSOMAL ABERRATION FREQUENCIES IN CHINESE HAMSTER OVARY CELLS

M. Murli

ABSTRACT

The objective of this assay was to evaluate the ability of PFDA to induce SCE and chromosomal aberrations in CHO cells both with and without S9 metabolic activation. In the SCE assay, duplicate cultures of CHO cells were incubated with target concentrations of PFDA ranging from 0.167 to 5000 $\mu g/mL$ in a half-log series. There was no significant increase in SCE at the concentrations tested.

No cell cycle delay was evident at the doses analyzed in the nonactivation SCE assay. Cell cycle delay was observed only at the highest dose of 167 $\mu g/mL$ in the SCE assay with metabolic activation. Based on the evaluation of cell cycle kinetics from the SCE assay, duplicate cultures of CHO cells were incubated with concentrations ranging from 7.50 to 200 $\mu g/mL$ in a 10-h nonactivation aberrations assay. Concentrations of 10.0 to 100 $\mu g/mL$ were tested in a 10-h aberrations assay and concentrations of 100 to 201 $\mu g/mL$ in a 20-h aberrations assay under conditions of metabolic activation. No significant increase in cells with chromosomal aberrations was observed in the nonactivation assay, but a significant increase was observed under conditions of metabolic activation. Therefore, PFDA was considered negative for inducing SCE and negative for inducing chromosomal aberrations in CHO cells under nonactivation conditions, but positive under the metabolic activation conditions of this assay.

INTRODUCTION

The chromosomes of dividing cells consist of two identical halves, or sister chromatids. SCEs are seen at metaphase of cell division as reciprocal interchanges of the two chromatid arms within a single chromosome. These exchanges presumably require enzymatic incision, translocation, and ligation of the two DNA strands. The frequency of SCE is thought to be a very sensitive indicator of damage to DNA and are caused by many chemical agents known to be mutagens or carcinogens.

The SCE assay involves treating cultured cells with a test compound, exposing the cells in culture to the thymidine analog BrdU for two cell cycles, and making chromosome preparations that are stained for SCE. By growing cells with BrdU for two cell cycles one chromatid contains half as much BrdU as the other and is stained more intensely by Giemsa, while its pair (the sister chromatid), is pale.

The chromosomal aberrations assay was designed to examine cells in the first mitosis after chemical exposure to establish whether the test article and/or its metabolites can interact with cells to induce chromosomal breaks. Aberrations are a consequence of failure or mistakes in repair processes resulting in breaks that do not rejoin or rejoin in abnormal configurations (Evans, 1962). Examining cells in the first mitosis after chemical exposure limits loss of aberrant cells during the division process or conversion into complex derivatives during subsequent cell cycles. In the case of CHO cells most dividing cells examined 8-12 h after treatment are in the first mitosis (M_1 cells). However, many test articles cause severe delay of progression

through the cell cycle, and the assay has been designed to detect this delay and allow for slower growth of damaged cells by adjustments in the time between treatment and cell fixation.

EXPERIMENTAL DESIGN

In the SCE assay, CHO cell cultures that were exposed to the test article for approximately two cell cycles were analyzed to determine cellular toxicity and effects of the test article on cell generation time. If necessary and possible, the assay was extended in cultures at affected doses to permit the progression to second generation cells. The doses used in the assay ranged from 0.167 to 5020 $\mu g/mL$ of the test material in a half-log series. Single cultures were used for the negative control, solvent control, and each of two doses for the positive control; duplicate cultures were used for the ten doses of the test material. SCE frequencies were analyzed from cultures treated with the four highest doses having second generation cells and from a negative, solvent, and positive control culture. Cell cycle kinetics of the treated cultures were also evaluated.

SUMMARY OF SCE ASSAY TREATMENT SCHEDULE IN HOURS (APPROXIMATE)

Test	Test Article	Wash	BrdU	Wash	Colcemid	Fixation
-S9	-2.25		0	22.75	23	25.5
+S9	-2.25	-0.25	0		23	25.5

Cell cycle kinetics from the SCE assay were used to determine the dose range to be used in the chromosomal aberrations assay and to determine the optimal time of harvest of the dosed cells so that primarily metaphase cells (in the first metaphase since exposure to the test article) would be analyzed for chromosomal aberrations. The aberrations assay was conducted at the 10-h harvest time for those chemicals that did not induce any cell cycle delay and at the 20-h harvest time for those chemicals that induced cell cycle delay.

In the chromosomal aberrations assay duplicate cultures were used for each dose. Single cultures were used for the negative control, solvent control, and at each of two doses for the positive control. In the nonactivation assay, 10- and 20-hour harvests were conducted while a 10-h harvest was conducted in the activation assay. Chromosomal aberrations were analyzed for the cultures treated at the four highest doses from which results could be obtained and from only one of the positive control doses. A summary of the treatment schedule for the chromosomal aberrations assays is given below.

SUMMARY OF CHROMOSOMAL ABERRATIONS ASSAY TREATMENT SCHEDULE IN HOURS (APPROXIMATE)

Test	Test Article	Wash	Colcemid	Fixation
-S9	0	7.25	7.5	10
-S9	0	17.2	17.5	20
+S9	0	2	7.5	10

39

MATERIALS AND METHODS

Test Material

The PFDA used in these studies was provided by the U.S. Air Force. The white, crystalline flakes were identified as Lot No. 1105ML and stored in its original container.

Indicator Cells

The CHO cells (CHO-WBL) used in this assay were from a permanent cell line and have been recloned to maintain karyotypic stability. This cell line has an average cycle time of 12 to 14 h with a modal chromosome number of 21.

Cell Culture Medium

The CHO cells were grown in McCoy's 5a culture medium that was supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin and streptomycin, at 37°C, in an atmosphere of 5% CO_2 in air.

Negative and Solvent Controls

In the nonactivation assays, negative controls were cultures that contained only cells and culture medium. Solvent controls were cultures containing the solvent in place of the test article at the same concentration used in test cultures. In the activation assays, the negative and solvent controls were the same as in the nonactivation assays but the S9 activation mixture was included.

Positive Control Agents

The positive control agents that were used in the assays were mitomycin C (MMC) for the nonactivation assays and cyclophosphamide (CP) for the metabolic activation assays. MMC is a clastogen that does not require metabolic activation, while CP must first be converted to active metabolites by microsomal enzymes. In the SCE assay two doses of MMC (0.005 μg/mL and 0.010 μg/mL) and CP (1.50 μg/mL and 2.00 μg/mL) were used. In the chromosomal aberrations assays two concentrations of MMC (0.500 μg/mL and 1.00 μg/mL, 10-h harvest; 0.040 μg/mL and 0.080 μg/mL, 20-h harvest) and CP (25.0 μg/mL and 50.0 μg/mL) were used. Only cultures exposed to one dose of the positive control were actually analyzed in each of the SCE and aberration assays.

Sister Chromatid Exchange Assays

In these assays, the cells were cultured for approximately 24 h prior to treatment by seeding approximately 0.8 x 10^6 cells per 75 cm^2 flask into 10 mL of complete McCoy's 5a culture medium. BrdU was added at a final concentration of 10 μM approximately 2 h after the initial exposure of the cells to the test article.

Nonactivation Assay: The cultures were dosed with the test article for approximately 2.5 h and then BrdU was added at a final concentration of 10 μM. The cultures were reincubated for approximately 23 h. Approximately 2.75 h prior to the harvest of the cells, the test article was washed from the cells with PBS and fresh culture medium containing BrdU (10 μM), and Colcemid (final concentration 0.1 μg/mL) was added.

Prior to the harvest of the cultures visual observations of toxicity were made. These observations included an assessment of the percent confluence of the cell monolayer within the culture flasks. The cultures were also evaluated for the presence of mitotic (large rounded cells) or dead cells

40

floating in the medium. Only flasks from the highest seven surviving doses from which metaphase cells for analysis were expected were harvested (See Section on Harvest).

The culture medium was collected and centrifuged. The mitotic cells were fixed and fresh culture medium was replaced on the remaining cell mcnolayer in the flasks. A test slide was made from fixed cells treated with the highest doses of test compound and stained with Hoechst 33258 stain (0..5 µg/mL in PBS, pH 6.8). The slides were examined under ultraviolet (UV) fluorescence microscopy. If there was a marked cell cycle delay, a second cell collection was made following an additional 6 h and mitotic cells were harvested. The harvested cells were differentially stained for the analysis of SCE using a modified fluorescence-plus-Giemsa (FPG) technique (See Sections on Harvest and Slide Preparation and Staining).

Assay with Metabolic Activation: In this assay, the CHO cells were exposed to the test article for 2 h in the presence of a rat liver S9 reaction mixture (S9 15 µL/mL, NADP 1.5 mg/mL, and isocitric acid 2.7 mg/mL). The S9 fraction was derived from the liver of male Sprague-Dawley rats treated with Aroclor 1254 to induce the mixed function oxidase enzymes and purchased from Molecular Toxicology Inc. The 2-h incubation time was chosen because prolonged exposure to the S9 mixture can be toxic to the cells and enzyme activity of S9 is lost rapidly at 37°C. The medium did not contain FBS during the exposure period because highly reactive or short-lived intermediates produced by the S9 enzymes can bind to serum proteins.

After the exposure period the cells were washed twice with PBS. Complete McCoy's 5a medium containing 10 µM BrdU was added to the cultures that were then incubated for approximately 23 h. Colcemid (final concentration 0.1 µg/mL) was then added, the cultures reincubated for 2.5 h, and the cells harvested and examined for any cell cycle delay. Slides were prepared and stained as described for the nonactivation assay. Delayed fixation was not required for any of the surviving cultures.

Chromosomal Aberrations Assay

Nonactivation Assay: Cultures were initiated by seeding approximately 1.0 x 10^6 cells (20-h assay) and 1.2 x 10^6 cells (10-h assay) per 75 cm^2 flask into 10 mL of complete McCoy's 5a medium. One day after culture initiation, the CHO cells to be used in the nonactivation assay were treated with the test article at predetermined doses for 7.25 and 17.25 h. The cultures were then washed with PBS and complete medium containing 0.1 µg/mL Colcemid was added back to the cultures. Two and one-half hours later the cells were harvested and air-dried slides were prepared and stained in 5% Giemsa solution for the analysis of chromosomal aberrations.

Assay with Metabolic Activation: Cultures were initiated by seeding approximately 1.2 x 10^6 cells per 75 cm^2 flask into 10 mL of complete McCoy's 5a medium. One day after culture initiation, the cultures were incubated at 37°C for 2 h in the presence of the test article and the S9 reaction mixture in McCoy's 5a medium without FBS. After the 2-h exposure period the cells were washed twice with PBS and complete medium was added back to the cultures. The cells were incubated for an additional 7.75 h with 0.1 µg/mL Colcemid added during the last 2.5 h of incubation. The metaphase cells were then harvested and prepared for cytogenetic analysis.

Harvest Procedure

The metaphase cells were collected by mitotic shake-off (Terasima and Tolmach, 1961) and were treated with 0.075 M KCl solution to swell the cells and disperse the chromosomes. The cultures were then fixed with an absolute methanol/glacial acetic acid (3:1, v/v) fixative and were washed several times before air-dried slides were prepared.

Slide Preparation and Staining

Slides were prepared by dropping the harvested cultures on clean slides. The slides from the rangefinding assays were differentially stained using a modified FPG technique (after Perry and Wolff, 1974; Goto et al., 1978). The slides were stained in Hoechst 33258 stain, exposed to UV light, and stained with Giemsa Azure B stain. Slides for analysis of chromosomal aberrations were stained with 5% Giemsa solution. All slides were then air-dried and coverslipped using Depex mounting medium.

SCE Analysis and Assay Evaluation

Fifty cells per dose were analyzed from each of the top four doses from which sufficient M_2 metaphase cells were available. Fifty cells were analyzed from each of the negative and solvent controls, and at least twenty cells were analyzed from one of the positive control doses. For control of bias, all slides except for the positive controls were coded prior to analysis. Cells were selected for scoring on the basis of good morphology and clear sister chromatid differentiation along the entire length of all chromosomes; only cells with the number of centromeres equal to the modal number 21 ± 2 (range of 19-23) were analyzed.

The slides were also examined for the presence of delayed cells. One hundred metaphase cells were scanned and classified as M_1, M_{1+}, or M_2 from each dose and the positive, negative, and solvent controls to give an estimate of cell cycle inhibition. In those doses where more than one harvest was conducted, cells were analyzed for cell cycle kinetics and SCE from the earliest harvest time from which sufficient M_2 cells were available for analysis. Controls were analyzed only at the normal harvest time (25-26 h). The cell cycle kinetics were presented as replicative index (RI), calculated using the formula $(1 \times M_1 + 1.5 \times M_{1+} + 2 \times M_2 + 2.5 \times M_{2+})/\#$ of cells analyzed (Schneider et al., 1981).

If an increase in SCE was observed, one of the following criteria must have normally been met to assess the compound as positive.

Two-fold increase: Approximately a doubling in SCE frequency over the "background" (solvent and negative control) levels at one or more doses.

Dose response: A positive assessment may be made in the absence of a doubling of the SCE frequency if there was a statistically significant increase at a minimum of three doses and evidence for a positive dose response.

In some cases, a statistically significant increase was observed with neither a doubling nor a dose response. These results were assessed according to the magnitude of the response, and the proportion of the doses affected.

Statistical analysis employed a Dunnett's one-tailed t-test (Bancroft, 1957; Hollander and Wolfe, 1973) to compare SCE frequencies in the tested cultures with that of the negative and solvent controls. The final evaluation of the test article was based upon scientific judgment.

Aberrations Analysis and Assay Evaluation

Cells were selected for good morphology and only cells with the number of centromeres equal to the modal number 21 ± 2 (range 19-23) were analyzed. One hundred cells, if possible, from each duplicate cultures at four doses of the test article and from each of the negative and solvent control cultures were analyzed for the different types of chromosomal aberrations (Evans, 1962). At least 25 cells were analyzed for chromosomal aberrations from one of the positive control cultures. For control of bias, all slides except for the positive controls were coded prior to analysis.

The following factors were taken into account in the evaluation of the chromosomal aberrations data:

    The overall chromosomal aberration frequencies.
    The percentage of cells with any aberrations.
    The percentage of cells with more than one aberration.
    Any evidence for increasing amounts of damage with increasing dose,
    i.e., a positive dose response.
    The estimated number of breaks involved in the production of the
    different types of aberrations which were observed, i.e., complex
    aberrations may have more significance than simple breaks.

Chromatid and isochromatid gaps, if observed, were noted in the raw data and were tabulated. They were not, however, considered in the evaluation of the ability of the test article to induce chromosomal aberrations since they may not represent true chromosomal breaks and may possibly be induced by toxicity.

A cell classified as "GT" was considered to contain 10 aberrations for statistical purposes but a ">" was also included in the tables for this classification to indicate that it is a minimum number.

Statistical analysis employed the Fisher's Exact Test with an adjustment for multiple comparisons (Sokal and Rohlf, 1981) to compare the percentage of cells with aberrations in each treatment group with the results from the pooled solvent and negative controls (the solvent and negative controls were statistically evaluated for similarity prior to the pooled evaluation). Test article significance was established where $p \leq 0.01$. All factors as stated previously were taken into account and the final evaluation of the test article was based upon scientific judgment.

RESULTS AND DISCUSSION

Solubility, Stability, and Dose Determination

The solubility of the test material was first tested in sterile deionized water and a thick gel like suspension formed at a concentration of -399 mg/mL that separated over time. A similar suspension was obtained at a concentration of -400 mg/ml in Pluronic F-68. A clear solution was obtained in DMSO at a concentration of 500 mg/mL. This solution was mixed with McCoy's 5a culture medium (1% v/v) and a slightly cloudy solution at a pH of -7.0 was obtained. DMSO was the solvent chosen and a target stock concentration of 500 mg/mL was prepared. A half-log series of target concentrations ranging from 0.167 to 5000 μg/mL was tested in the SCE assay

SCE Assay

Nonactivation Assay: In the first trial of the SCE assay only single flasks were dosed. Therefore a second trial was conducted. The results from this first trial were used for analysis of cell cycle kinetics. Complete cytotoxicity was observed at concentrations of 167 μg/mL and higher. No toxicity was observed in the other test cultures. Cell cycle kinetics were analyzed at 5.01, 16.7, and 50.1 μg/ml and no cell cycle delay was observed at these doses. Based on these cell cycle kinetics, a 10-h harvest was selected for testing concentrations of 7.50, 10.0, 25.0, 50.0, 75.0, 100, 150, and 200 μg/mL in the aberrations assay without metabolic activation.

In Trial 2 of the SCE assay, complete cytotoxicity was again observed at concentrations of 167 μg/mL and higher. A slight reduction in the number of visible mitotic cells and an approximately 15% reduction in the cell monolayer confluence were observed at a concentration of 50.0 μg/mL. SCE were analyzed from cultures exposed to concentrations of 1.67, 5.00, 16.7, and 50.0 μg/mL (Table 5-1). No significant increase in SCE was observed at the concentrations analyzed. The sensitivity of the cell culture for induction of SCE was demonstrated by the increased frequency of SCE in the cells exposed to the positive control agent. PFDA was considered negative for inducing SCE under conditions of nonactivation.

TABLE 5-1. SISTER CHROMATID EXCHANGE IN CHO CELLS WITHOUT METABOLIC ACTIVATION OF PFDA

	Dose μg/mL	Total Cells Scored	# of Chromo- somes	# of SCE	SCE/ Chromo- some	SCE/Cell Mean ± SE	RI	% SCE Increase Over Solvent	Confluence % Solvent Control
McCoys 5a	-----	50	1028	325	0.32	6.50 ± 0.37	1.91		
DMSO[a]	-----	50	1038	377	0.36	7.54 ± 0.43	1.75		100
MMC	0.010	20	413	708	1.71	35.40 ± 1.69*	1.82	372	100
PFDA	1.67	50	1040	365	0.35	7.30 ± 0.44	1.80		100
PFDA	5.00	50	1043	383	0.37	7.66 ± 0.47	1.80	1	100
PFDA	16.7	50	1042	397	0.38	7.94 ± 0.33	1.82	5	100
PFDA	50.0	50	1040	394	0.38	7.88 ± 0.46	1.86	4	100
PFDA	167**								

[a] Concentration of DMSO = 1% v/v.

* Significantly greater than the solvent control, p < 0.05.

** Toxic dose.

Assay With Metabolic Activation: In the first trial of the SCE assay only single flasks were dosed and hence the SCE assay was repeated. The results from this assay were, however, used for analysis of cell cycle kinetics. Complete cytotoxicity was observed at concentrations of 501, 1670, and 5010 μg/mL. A slightly unhealthy cell monolayer, an approximately 30% reduction in the cell monolayer confluence, floating dead cells and debris, and a severe reduction in the number of visible mitotic cells were observed at a concentration of 167 μg/mL. No toxicity was observed in the other test cultures. Cell cycle kinetics were analyzed from cultures exposed to concentrations of 1.67, 5.01, 16.7, 50.1, and 167 μg/mL. Severe cell cycle delay was observed at a concentration of 167 μg/mL. Based on these cell cycle

kinetics, a 10-h harvest was selected for testing concentrations of 10.0, 25.0, 50.0, 75.0, and 100 μg/mL, and a 20-h harvest was selected for testing concentrations of 100, 151, and 201 μg/mL in the aberrations assay with metabolic activation.

In Trial 2 of the SCE assay, complete cytotoxicity was observed at concentrations of 500, 1670, and 5000 μg/mL. A slight reduction in the number of visible mitotic cells and an approximately 15% reduction in the cell monolayer confluence were observed at a concentration of 167 μg/mL. SCE was analyzed at concentrations of 5.00, 16.7, 50.0, and 167 μg/mL (Table 5-2). A weakly significant increase was observed only at a concentration of 16.7 μg/mL. No significant increase in SCE was observed at the other concentrations analyzed. The successful activation of the metabolic system was illustrated by the increased frequency of SCE in the cells induced with the positive control agent. Because the significant increase observed at a concentration of 16.7 μg/mL was not present in cultures exposed to the higher doses and because no positive dose relationship was observed, the test article was considered negative for inducing SCE under conditions of metabolic activation.

TABLE 5-2. SISTER CHROMATID EXCHANGE IN CHO CELLS WITH METABOLIC ACTIVATION OF PFDA

	Dose μg/mL	Total Cells Scored	# of Chromo-somes	# of SCE	SCE/ Chromo-some	SCE/Cell Mean ± SE	RI	% SCE Increase Over Solvent	Confluence % Solvent Control
McCoys 5a	-----	50	1045	317	0.30	6.34 ± 0.34	1.94		
DMSO[a]	-----	50	1040	354	0.34	7.08 ± 0.40	1.92		100
CP	1.50	20	414	615	1.49	30.75 ± 2.37*	1.89	336	100
PFDA	5.00	50	1042	349	0.33	6.98 ± 0.42	1.96		100
PFDA	16.7	50	1047	416	0.40	8.32 ± 0.38*	1.93	17	100
PFDA	50.0	50	1038	305	0.29	6.10 ± 0.25	1.94		100
PFDA	167	50	1035	396	0.38	7.92 ± 0.44	1.75	12	100
PFDA	500**								

[a] Concentration of DMSO = 1% v/v.

* Significantly greater than the solvent control, p < 0.05.

** Toxic dose.

Chromosomal Aberrations Assay

Nonactivation Assay: A slightly unhealthy cell monolayer and a reduction in the number of visible mitotic cells was observed at a concentration of 200 μg/mL. No toxicity was observed in the other test cultures. Results were analyzed from cultures exposed to concentrations of 75.0, 100, 150, and 200 μg/mL (results pooled from the replicate cultures are presented in Table 5-3, and results from individual cultures are presented in Table 5-4). No significant increase in cells with chromosomal aberrations was observed at the concentrations analyzed. The sensitivity of the cell culture for induction of chromosomal aberrations was demonstrated by the increased frequency of aberrations in the cells exposed to the positive control agent. The test article was considered negative for inducing chromosomal aberrations under nonactivation conditions.

45

**TABLE 5-3. CHROMOSOME ABERRATIONS IN CHO CELLS WITHOUT
METABOLIC ACTIVATION OF PFDA
(RESULTS FROM DUPLICATE CULTURES)**

		Not Computed			Simple			Complex						Other	No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
	Cells Scored	TG	SG	UC	TB	SB	DM	ID	TR	OR	CR	R	CI	GT			
Media + DMSO	200	8				1									0.01	0.5	0.0
MMC (0.5 µg/mL)	25	5	1		1	3		1	3	5					0.52	40.0*	8.0*
Test Article																	
75.0 µg/mL	200	9	2			3									0.02	1.0	0.5
100 µg/mL	200	11													0.00	0.0	0.0
150 µg/mL	200	5													0.00	0.0	0.0
200 µg/mL	200	18	2		1					1					0.01	1.0	0.0

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

**TABLE 5-4. CHROMOSOME ABERRATIONS IN CHO CELLS WITHOUT
METABOLIC ACTIVATION OF PFDA
(RESULTS FROM INDIVIDUAL CULTURES)**

		Not Computed			Simple			Complex						Other	No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
	Cells Scored	TG	SG	UC	TB	SB	DM	ID	TR	OR	D	R	CI	GT			
Controls																	
McCoy's 5a	100	4													0.00	0.0	0.0
1% v/v DMSO	100	4				1									0.01	1.0	0.0
MMC (0.500 µg/mL)	25	5	1		1	3		1	3	5					0.52	40.0*	8.0*
Test Article																	
75.0 µg/mL A	100	3													0.00	0.0	0.0
75.0 µg/mL B	100	6	2			3									0.03	2.0	1.0
100 µg/mL A	100	8													0.00	0.0	0.0
100 µg/mL B	100	3													0.00	0.0	0.0
150 µg/mL A	100														0.00	0.0	0.0
150 µg/mL B	100	5													0.00	0.0	0.0
200 µg/mL A	100	9	1		1										0.01	1.0	0.0
200 µg/mL B	100	9	1							1					0.01	1.0	0.0

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

Assay With Metabolic Activation: In the 10-h assay, no toxicity was observed in any of the test cultures. Results were analyzed from cultures exposed to concentrations of 75.0 and 100 µg/mL (results pooled from the replicate cultures are presented in Table 5-5, and results from individual cultures are presented in Table 5-6). No significant increase in cells with chromosomal aberrations was observed at the doses analyzed.

TABLE 5-5. CHROMOSOME ABERRATIONS IN CHO CELLS
WITH METABOLIC ACTIVATION OF PFDA
(RESULTS FROM DUPLICATE CULTURES, 10-HOUR INCUBATION)

	Cells Scored	Not Computed			Simple				Complex					Other	No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
		TG	SG	UC	TB	SB	DM	ID	TR	QR	CR	R	CI	GT			
Media and DMSO	200	8	1												0.00	0.0	0.0
CP (25.0 µg/mL)	50	4	1		1	6		5	5	4	1				0.44	38.0*	6.0*
Test Article 75.0 µg/mL	200	2													0.00	0.0	0.0
100 µg/mL	200	4			3	1									0.02	2.0	0.0

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

TABLE 5-6. CHROMOSOME ABERRATIONS IN CHO CELLS WITH
METABOLIC ACTIVATION OF PFDA
(RESULTS FROM INDIVIDUAL CULTURES, 10-HOUR INCUBATION)

	Cells Scored	Not Computed			Simple				Complex					Other	No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
		TG	SG	UC	TB	SB	DM	ID	TR	QR	CR	R	CI	GT			
McCoy's 5a	100	6	1												0.00	0.0	0.0
DMSO 1% v/v	100	2													0.00	0.0	0.0
CP (25.0 µg/mL)	50	4	1		1	6		5	5	4	1				0.44	38.0*	6.0*
Test Article 75.0 µg/ml A	100	1													0.00	0.0	0.0
B	100	1													0.00	0.0	0.0
100 µg/ml A	100	2													0.00	0.0	0.0
B	100	2			3	1									0.04	4.0	0.0

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

In the 20-h assay, a slight reduction in the number of visible mitotic cells and an approximately 30% reduction in the cell monolayer confluence was observed at a concentration of 201 µg/mL. No toxicity was observed in the other test cultures. Results were analyzed from cultures exposed to concentrations of 100, 151, and 201 µg/mL (results pooled from the replicate cultures are presented in Table 5-7, and results from individual cultures are presented in Table 5-8). A significant increase in cells with chromosomal aberrations was observed in cultures exposed to concentrations of 151 and 201 µg/mL. The breaks observed were complex chromatid type aberrations typical of chemical clastogens. The successful activation of the metabolic system was illustrated by the increased incidence of cells with chromosomal aberrations in the cultures induced with CP, the positive control agent. The test article was therefore considered positive for inducing chromosomal aberrations under conditions of metabolic activation.

CONCLUSION

PFDA was considered negative for inducing SCEs in CHO ovary cells under both the metabolic activation and nonactivation conditions of this assay. The test article was also considered negative for inducing chromosomal aberrations under nonactivation conditions, but caused a significant increase in chromosomal aberrations under the metabolic activation conditions of this assay.

TABLE 5-7. CHROMOSOME ABERRATIONS IN CHO CELLS
WITH METABOLIC ACTIVATION OF PFDA
(RESULTS FROM DUPLICATE CULTURES, 20-HOUR INCUBATION)

	Cells Scored	Number and Type of Aberration													No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
		Not Computed			Simple				Complex					Other			
		TG	SG	UC	TB	SB	DM	ID	TR	QR	CR	D	CI	GT			
Media and DMSO	200	4	3			1						1			0.01	1.0	0.0
CP (12.5 µg/mL)	25	2			4	13		1	13	8			1		1.60	100.0*	48.0*
Test Article																	
100 µg/mL	200	7	1												0.00	0.0	0.0
151 µg/mL	200	12	2		3	3			1	3	1	1	2		0.07	5.5*	1.0
201 µg/mL	200	39	6		25	20		5	10	12	2	1	3	12	>0.99	25.0*	14.0*

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

TABLE 5-8. CHROMOSOME ABERRATIONS IN CHO CELLS WITH METABOLIC ACTIVATION OF PFDA (RESULTS FROM INDIVIDUAL CULTURES, 20-HOUR INCUBATION)

	Cells Scored	Number and Type of Aberration													No. of Aberrations Per Cell	% Cells with Aberrations	% Cells with >1 Aberration
		Not Computed			Simple					Complex				Other			
		TG	SG	UC	TB	SB	DM	ID	TR	QR	CR	D	CI	GT			
McCoy's 5a	100	3	1												0.00	0.0	0.0
DMSO 1% v/v	100	1	2			1			1						0.02	2.0	0.0
CP (12.5 µg/mL)	25	2			4	13		1	13	8			1		1.60	100.0*	48.0*
Test Article																	
100 µg/ml A	100	2													C.00	0.0	0.0
100 µg/ml B	100	5	1												0.00	0.0	0.0
151 µg/ml A	100	4			1	1			1	1					0.04	4.0	0.0
151 µg/ml B	100	8	2		2	2				2	1	1	2		0.10	7.0	2.0
201 µg/ml A	100	20	2		9	8	5		6	9	1	1	2	4	>0.81	23.0*	13.0*
201 µg/ml B	100	19	4		16	12			4	3	1		1	8	>1.17	27.0*	15.0*

* Significantly greater than the pooled negative and solvent controls, p < 0.01.

REFERENCES

Bancroft, H. 1957. *Introduction to Biostatistics.* Hoeber-Harper.

Evans, H.J. 1962. Chromosomal aberrations produced by ionizing radiation. *International Review of Cytology* 13:221-321.

Goto, K., S. Maeda, Y. Kano, and T. Sugiyama. 1978. Factors involved in differential Giemsa-staining of sister chromatids. *Chromosoma* 66:351-359.

Hollander, M. and D.A. Wolfe. 1973. *Nonparametric Statistical Methods*, John Wiley and Sons.

Perry, P. and S. Wolff. 1974. New Giemsa method for the differential staining of sister chromatids. *Nature*, 251:156-158.

Schneider, E.L., Y. Nakanishi, J. Lewis, and H. Sternberg. 1981. Simultaneous examination of sister chromatid exchanges and cell replication kinetics in tumor and normal cells in vivo. *Cancer Res.*, 41:4973-4975.

Sokal, R.R. and F. J. Rohlf, F.J. 1981. *Biometry*, Ed. 2, W.H. Freeman and Company, New York.

Terasima, T. and L.J. Tolmach. 1961. Changes in X-ray sensitivity of HeLa cells during the division cycle. *Nature*, 190:1210-1211 .

APPENDIX 5-A

DEFINITIONS OF CHROMOSOME ABERRATIONS FOR GIEMSA STAINED CELLS

NOT COMPUTED

TG   Chromatid Gap: ("tid gap"). An achromatic (unstained) region in one chromatid, the size of which is equal to or smaller than the width of a chromatid. These are noted but not usually included in final totals of aberrations as they may not all be true breaks.

SG   Chromosome Gap: ("isochromatid gap, IG"). Same as chromatid gap but at the same locus in both sister chromatids.

UC   Uncoiled Chromosome: Failure of chromatin packing. Probably not a true aberration.

PP   Polyploid cell: A cell containing multiple copies of the haploid number (n) of chromosomes. Only indexed if very common. Not counted in the cells scored for aberrations.

E   Endoreduplication: 4n cell in which separation of chromosome pairs has failed. Only indexed if very common. Not counted in the cells scored for aberrations.

SIMPLE

TB   Chromatid Break: An achromatic region in one chromatid, larger than the width of a chromatid. The associated fragment may be partially or completely displaced.

SB   Chromosome Break: Chromosome has a clear break, forming an abnormal (deleted) chromosome with an acentric fragment (AF) that is dislocated. This classification now includes the AF. The AF was different from the SB only in that it was not apparently related to any specific chromosome.

DM   "Double Minute" fragment: These are small double dots, some of which are terminal deletions and some interstitial deletions and probably small rings. Their origins are not distinguishable.

COMPLEX

ID   Interstitial Deletion: Length of chromatid "cut out" from midregion of a chromatid resulting in a small fragment or ring lying beside a shortened chromatid or a gap in the chromatid.

TR   Triradial: An exchange between two chromosomes, or one chromosome and an AF, which results in a three-armed configuration.

QR   Quadriradial: As triradial, but resulting in a four-armed configuration.

CR	Complex Rearrangement:	An exchange among more than two chromosomes or fragments which is the result of several breaks.
D	Dicentric:	An exchange between two chromosomes which results in a chromosome with two centromeres. This is often associated with an AF in which case it is classified as DF.
DF		Dicentric with fragment.
TC	Tricentric:	An exchange involving three chromosomes and resulting in a chromosome with three centromeres. Often associated with two to three AF. Such exchanges can involve many chromosomes and are named as follows:
QC	Quadricentric:	four centromeres, up to four AF
PC	Pentacentric:	five centromeres, up to five AF
HC	Hexacentric:	six centromeres, up to six AF
R	Ring:	A chromosome which forms a circle containing a centromere. This is often associated with an acentric fragment in which case it is classed as RF.
RC	Ring Chromatid:	Single chromatid ring (acentric).
RF		Ring with associated AF.
CI	Chromosome Intrachange:	Exchange within a chromosome; e.g., a ring that does not include the entire chromosome.
T	Translocation:	Obvious transfer of material between two chromosomes resulting in two abnormal chromosomes. When identifiable, scored as "T" not "2Ab."
AB		Abnormal monocentric chromosome. This is a chromosome whose morphology is abnormal for the karyotype, and often the result of a translocation, pericentric inversion, etc. Classification used if abnormality cannot be ascribed to; e.g., a reciprocal translocation.

OTHER

GT/>	A cell which contains more than 10 aberrations. A heavily damaged cell should be analyzed to identify the types of aberrations and may not actually have > 10, e.g., multiple fragments such as those found associated with a tricentric.

SECTION 6

MUTAGENICITY TEST ON PFDA IN THE
IN VIVO/IN VITRO RAT PRIMARY HEPATOCYTE
UNSCHEDULED DNA SYNTHESIS AND S-PHASE INDUCTION ASSAYS

M.A. Cifone

ABSTRACT

In the *In Vivo/In Vitro* Rat Primary Hepatocyte UDS assay, PFDA did not induce significant changes in the nuclear labeling of rat hepatocytes over a dose range of 5.5 to 44.0 mg/kg. Three male F344 rats were treated by oral gavage at each of four doses with the test material suspended in corn oil. At 15.3 to 15.7 h after treatment with the test material, primary hepatocyte cultures were prepared. Viabilities of the hepatocytes obtained ranged from 77.8 to 94.7%. After attachment, the cultures were incubated with 10 μCi/mL ^{3}HTdr (50 Ci/mmole) for 4 h. The cultures were prepared for analysis of nuclear labeling 16.3 to 18.9 h after removal of the radioactivity and addition of 0.25 mM unlabeled thymidine. None of the criteria used to indicate UDS were approached by the treatments and no dose-related response was observed. PFDA was therefore evaluated as inactive in the UDS assay. Although UDS activity was not observed at the 15 to 16-h timepoint, a significant elevation in S-phase DNA synthesis that met the criteria for a positive response was observed and addressed as part of the S-phase induction assay.

In the *In Vivo/In Vitro* Rat Primary Hepatocyte DNA Synthesis (S-Phase) Induction assay, PFDA induced a significant increase in the number of S-phase cells over a dose range of approximately 5.5 to 44.0 mg/kg. At least three male F344 rats were treated by oral gavage at each of four doses with the test material suspended in corn oil. At 48.1 to 48.4 h following dosing, primary hepatocyte cultures were prepared for analysis of S-phase synthesis. Viabilities of the hepatocytes prepared for S-phase analysis ranged from 78.4 to 94.5%. After attachment, the cultures were incubated with 10 μCi/mL ^{3}HTdr (50 Ci/mmole) for 4.0 to 4.1 h. The cultures were prepared for analysis of labeling 16.8 to 18.8 h after removal of the radioactivity and addition of 0.25 mM unlabeled thymidine. A statistically significant elevation in the level of S-phase cells was observed in the hepatocyte cultures prepared from rats receiving 11 and 22.0 mg/kg of test article. At both doses of 5.5 and 44.0 mg/kg only a single animal responded. In addition to the positive responses observed at the 48-h timepoint, a significant elevation in S-phase synthesis was also observed at the 15 to 16-h timepoint at doses of 11.0, 22.0, and 44.0 mg/kg. PFDA therefore evaluated as active in the *In Vivo/In Vitro* Rat Hepatocyte DNA Synthesis (S-Phase) Induction Assay.

INTRODUCTION

These assays were designed to measure unscheduled DNA synthesis (UDS) or S-phase (replicative DNA synthesis) in rat liver cells using the techniques described by Williams (1980). Fresh hepatocytes obtained from rat liver will attach to a surface in culture and continue to metabolize for several days without undergoing cell division. Only a small percentage of the cells will enter S-phase. Therefore, if ^{3}HTdr is introduced into the culture medium, little or no label will be incorporated into nuclear DNA. Pretreatment of rats with a test material that interacts with the DNA will stimulate a repair response in which the altered portion of DNA is excised and the missing region replaced by DNA synthesis. This synthesis of DNA by nondividing cells is known as UDS and can be measured by determining the amount of ^{3}HTdr

incorporated into DNA. This measurement of DNA repair appears to correlate very well with the known mutagenic or carcinogenic activities of chemicals (Williams, 1980). The use of autoradiographic techniques affords simultaneous measurements of UDS and S-phase in hepatocyte cultures because S-phase cells are very heavily labeled and easily distinguished from lightly labeled cells exhibiting UDS. Hepatotoxicants such as carbon tetrachloride and dinitrotoluene induce an increase in cell proliferation to replace necrotic tissue (Butterworth et al., 1987; Mirsalis and Butterworth, 1982). Other compounds may induce S-phase synthesis in the absence of hepatotoxicity.

The objective of this assay was to detect DNA damage caused by the test material, or an active metabolite, by measuring UDS or S-phase induced in rat primary hepatocytes *in vivo*. The existence and degree of DNA damage was inferred from an increase in net nuclear grain (NNG) counts in hepatocytes obtained from treated animals when compared to those from untreated animals. The types of DNA damage are unspecified but must be recognizable by the cellular repair system and result in the incorporation of new bases (including ³HTdr) into DNA during a short *in vitro* culture period. Quantitation of cells in S-phase has been shown to be useful for the evaluation of chemicals that may cause increased cell proliferation in the liver (Butterworth et al., 1987).

MATERIALS AND METHODS

Indicator Cells

The indicator cells for the UDS assay were hepatocytes obtained from adult male F344 rats weighing from 180.5 to 199.6 g, purchased from Charles River Breeding Laboratories, Incorporated. The animals used for the S-phase assay were obtained from the same supplier and weighed from 180.0 to 203.9 g. The animals were fed Purina Certified[R] Rodent Chow (Formula 5002) and water *ad libitum*. Animals were identified by ear tag after random assignment to the study and were quarantined a minimum of five calendar days prior to use.

Animals were anesthetized prior to surgery using 60 mg/kg pentobarbital and were exsanguinated during the liver perfusion. The cells were obtained by perfusion of the livers *in situ* with media containing type II collagenase. Monolayer cultures were established in culture dishes and were used the same day for analysis of the UDS or S-phase activity. All cultures were maintained as monolayers at 37°C in a humidified atmosphere containing approximately 5% CO_2.

Media

The cell cultures were established in Williams' Medium E supplemented with 10% FBS, 2 mM L-glutamine, 100 μg/mL streptomycin sulfate, and 150 μg/mL gentamycin (WME+). WME+ without serum is referred to as WMEI. After the establishment period, cultures were refed with WMEI containing 10 μCi/mL ³HTdr, (WMEI-treat).

Controls

A vehicle control consisting of a minimum of three rats treated with corn oil by oral gavage was performed in all cases and at all timepoints. The dosing volumes did not exceed 2.03 mL/kg (a target of 2.0 mL/kg ± 10%).

The positive control article used is known to induce UDS *in vivo* in rat hepatocytes. DMN, delivered by ip injection at approximately 15 mg/kg, was used for the UDS timepoint. For the S-phase timepoint, DMN was administered by ip injection at 20 mg/kg.

Test Article

PFDA (96%, Lot No. 1105M1) was obtained from the U.S. Air Force. The white flakes were stored in the original container.

Dosing Procedure

For both the UDS and S-phase assays, rats were treated by oral gavage with the test article suspended in corn oil by mechanical homogenization. The total volume of the test article solution administered did not exceed 2.2 mL/kg (target of 2.0 mL/kg ± 10%). DMN was solubilized in sterile deionized water and dosed as described previously. Fresh preparations of test article in vehicle were used for all testing purposes.

Dose Selection and Perfusion Time

For the UDS assay, the highest dose selected was 44 mg/kg. Three additional doses of test material were prepared using approximate 2-fold dilutions and a minimum of 3 animals per dose. The timepoint for harvesting hepatocytes for the UDS assay was 15.3 to 15.7 h after the administration of a single dose of the test article by oral gavage.

A dose of 44 mg/kg was selected as the maximum dose for the S-phase induction assay. Three additional doses of test material were prepared using approximate 2-fold dilutions and a minimum of 3 animals per dose. S-phase analysis was performed at 48.1 to 48.4 h after the administration of a single dose of the test article by oral gavage.

UDS and S-Phase Assays

These assays were based on the procedures described by Williams (1980), Mirsalis, Tyson, and Butterworth (1982), and Butterworth et al., (1987). The hepatocytes for both assays were obtained by perfusion of livers *in situ* for two to four min with Hanks' balanced salts (Ca^{++} - Mg^{++}-free) containing 0.5 mM ethyleneglycol-bis (ß-aminoethyl ether)-N, N-tetraacetic acid, and HEPES buffer at pH 7.2. Following this, WMEI containing 50-100 U/mL of Type II collagenase was perfused through the liver for 10 to 11 min. The hepatocytes were obtained by mechanical dispersion of excised liver tissue in a culture dish containing the WMEI culture medium and collagenase. The suspended tissue and cells were allowed to settle to remove cell clumps and debris. The cell suspension was centrifuged and the cell pellet resuspended in WME+. After obtaining a viable cell count, a series of 35-mm culture dishes (at least 6 per animal containing a 25-mm round, plastic coverslip and at least 2 per animal to assess attachment efficiency) was inoculated with approximately 0.5×10^6 viable cells in 3 mL of WME+ per dish.

An attachment period of 1.5 to 2 h at 37°C in a humidified atmosphere containing 5% CO_2 was used to establish the cell cultures. Unattached cells were then removed and the cultures were refed with 2.5 mL WME-treat. Any remaining cultures were kept for analysis in the event of technical problems with autoradiography. Attachment efficiency was determined for two cultures from each animal using trypan blue dye exclusion and *in situ* analysis.

After a labeling period of 4 h labeled cultures were refed with WMEI containing 0.25 mM unlabeled thymidine. The cells were returned to the incubator for 16 to 20 h. After the incubation period, the hepatocyte nuclei were swollen by addition of 1% sodium citrate to the coverslips (containing the cell monolayers) for 10 min. The cells were fixed in acetic acid:ethanol (1:3) and dried for at least 24 h. The fixed coverslips were mounted on glass slides, dipped in Kodak NTB2 emulsion, and dried. The emulsion coated slides were stored for seven days (for UDS assay) or eight days (for S-Phase assay)

at 4°C in light-tight boxes containing Drierite. The emulsions were then developed in D19, fixed, and stained with Williams' modified hematoxylin and eosin procedure.

For the UDS assay the cells were examined microscopically at approximately 1500x magnification under oil immersion and the field was displayed on the video screen of an automatic counter. UDS was measured by counting nuclear grains and subtracting the average number of grains in three nuclear-sized areas adjacent to each nucleus (background count). This value is referred to as the NNG count. The coverslips were coded to prevent bias in grain counting.

The NNG count was determined for fifty randomly selected cells on each coverslip analyzed for UDS, unless otherwise indicated. The cells were counted by positioning the slide under the microscope in the upper right section of the slide and noting the vertical vernier. The first ten analyzable cells were counted moving the field to the left. After counting ten cells, the slide was moved vertically to another position and counting resumed. This process was repeated until fifty cells on the slide were counted. Only nuclei that appeared normal were scored, and any occasional nuclei blackened by grains too numerous to count were excluded as cells in which replicative DNA synthesis occurred rather than repair synthesis. The mean NNG count was determined from triplicate coverslips (150 total nuclei) for each animal and from at least two animals per treatment condition.

Cells undergoing DNA replication were easily distinguished from nonreplicating cells in autoradiographic preparations. For the S-phase time point (48 h), the percentage of cells in S-phase (%S) was calculated manually as those cells exhibiting nuclei blackened by grains too numerous to count. At least 2000 cells were counted from randomly selected areas of each slide. Replicating and nonreplicating cells were counted separately using a two-position hand counter. For each dose, 6000 cells were scored for each of 3 animals (18,000 total cells per dose), unless indicated otherwise.

RESULTS AND DISCUSSION

UDS Assay

PFDA was suspended in corn oil at concentrations ranging from 2.85 to 22.3 mg/mL. Each dose for the UDS assay (with the exception of the 5.50 mg/kg dose) was prepared by two-fold serial dilutions with corn oil after preparation of an initial stock solution of 22.3 mg/mL. The test material formed a suspension of heterogeneous flakes in the vehicle and was therefore mechanically homogenized prior to dilution or dosing. Groups of three rats were each dosed with 44.0, 22.0, 11.0, and 5.50 mg/kg by oral gavage in volumes which did not exceed 2.2 ml/kg.

Perfusions were initiated 15.3 to 15.7 h after administration of a single dose of the test article by oral gavage. The hepatocytes collected for the UDS assay ranged in viability (determined by trypan blue exclusion) from 77.8 to 94.7% of the total cells collected in the perfusate (Table 6-1). The attachment efficiency varied from 59.3 to 90.0% and the viability of the attached cells was very good, ranging from 84.8 to 95.5%.

The minimum criteria for a UDS response were determined by comparison with the average of the concurrent vehicle control treatments. A positive response consisted of mean net nuclear grain counts exceeding 5.78 (5 above the average net grains of 0.78) or at least 20.5% of the nuclei containing 5 or more grains (10% above the average of 10.5%). None of the treatments with the test material samples caused nuclear labeling significantly different from the vehicle control (Table 6-2). Furthermore, no dose-related trend was evident. In contrast, the DMN treatments induced a large increase in nuclear

labeling that exceeded both criteria used to indicate UDS (See Appendix 6-A).
Because the positive control animals were responsive to DMN, the test results
were considered to provide conclusive evidence for the lack of UDS induction
by the test material samples.

Heavily labeled nuclei (blackened with numerous grains) represent cells
undergoing DNA replication as opposed to DNA repair. The number present in
the controls in the UDS study was low and did not interfere with the assay.
Only 38 cells (0.42%) among the 9000 control cells screened in the assay were
heavily labeled.

**TABLE 6-1. SUMMARY OF CULTURE DATA FOR HEPATOCYTES FROM RATS[a] TREATED WITH
PFDA (16-HOUR TIMEPOINT)**

Target Dose (mg/kg)	Animal Number	Perfusion Viability (%)	Attachment[b] Efficiency (%)	Attachment[b] Viability (%)
VC[c]	3315	89.3	82.5	92.9
VC	3325	84.4	69.7	88.1
VC	3332	90.6	73.4	91.3
DMN[d]	3320	77.8	73.6	90.8
DMN	3326	91.6	66.3	91.2
DMN	3329	83.0	59.3	89.0
5.50	3319	88.0	71.4	90.2
5.50	3321	93.4	66.1	93.5
5.50	3327	89.9	72.0	92.3
11.0	3316	89.2	68.1	84.8
11.0	3317	89.9	72.9	88.1
11.0	3330	92.3	70.1	93.2
22.0	3318	94.7	72.9	95.5
22.0	3328	85.2	71.1	89.6
22.0	3331	94.2	64.6	95.2
44.0	3322	88.0	76.5	87.0
44.0	3323	80.8	64.5	85.2
44.0	3324	83.5	90.0	95.0

[a] Three animals per dose were treated.
[b] Results based on viable counts (trypan blue dye exclusion) of randomly
selected areas on two plates.
[c] VC = Vehicle Control (corn oil, 2 mL/kg).
[d] DMN = Dimethylnitrosamine 15 mg/kg).

**TABLE 6-2. UDS DATA SUMMARY FOR HEPATOCYTES FROM RATS[a]
TREATED WITH PFDA (16-HOUR TIMEPOINT)**

Target Dose (mg/kg)	Animal Number	Net Nuclear Grains ± SD[b]	Mean Cyto Grains[c]	% Nuclei with ≥5 Net Grains[c]	% S[d]
VC[e]	3315	0.28 ± 0.26	5.68	4.7	0.47
VC	3325	0.19 ± 0.68	6.50	8.0	0.13
VC	3332	1.87 ± 0.19	6.31	18.7	0.93
DMN[f]	3320	8.67 ± 1.05	5.98	73.3	0.27
DMN	3326	10.44 ± 0.50	5.51	72.7	0.20
DMN	3329	6.01 ± 0.46	5.96	57.3	0.53
5.50	3319	-1.05 ± 0.08	7.95	0.0	0.40
5.50	3321	-0.37 ± 0.31	10.59	7.3	2.13*
5.50	3327	0.62 ± 0.23	9.62	10.0	0.73
11.0	3316	-0.51 ± 0.05	8.69	2.0	2.80*
11.0	3317	0.09 ± 0.99	10.07	8.7	1.47*
11.0	3330	-0.62 ± 0.24	8.06	1.3	0.93
22.0	3318	-0.32 ± 1.16	8.57	8.0	1.80*
22.0	3328	-1.17 ± 0.27	8.47	2.0	3.00*
22.0	3331	-0.77 ± 0.28	10.23	0.7	4.93*
44.0	3322	0.93 ± 0.57	7.63	14.7	1.60*
44.0	3323	1.17 ± 0.22	10.51	16.0	2.67
44.0	3324	1.12 ± 0.00	6.94	10.0	1.40*

[a] Three animals per dose were treated.

[b] Average of NNG counts on triplicate coverslips (150 total cells), ± standard deviation between coverslips.

[c] Average values for triplicate coverslips.

[d] Percent of S-phase nuclei on triplicate coverslips (1500 total cells scored)

[e] VC = Vehicle control (corn oil, 2 mL/kg).

[f] DMN = Dimethylnitrosamine (15 mg/kg).

* Statistically significant difference compared to the average of the pooled vehicle controls p < 0.05.

S-Phase Assay

PFDA was suspended in corn oil at concentrations ranging from 2.81 to 22.6 mg/mL. All dosing stocks for the S-phase analysis were prepared individually, just prior to use. In order to determine the amount of cell proliferation induced by the test material, three rats per dose were sacrificed at 48.1 to 48.4 h after a single doses of 44.0, 22.0, 11.0, and 5.5 mg/kg was administered.

The hepatocytes collected for S-phase analysis ranged in viability (determined by trypan blue exclusion) from 78.4 to 94.5% of the total cells collected in the perfusate (Table 6-3). The attachment efficiency varied from 56.9 to 84.8% and the viability of the attached cells was very good, ranging from 83.1 to 96.6%.

**TABLE 6-3. CULTURE DATA SUMMARY FOR HEPATOCYTES FROM RATS[a]
TREATED WITH PFDA (48-HOUR TIMEPOINT)**

Target Dose (mg/kg)	Animal Number	Perfusion Viability (%)	Attachment[b] Efficiency (%)	Attachment[b] Viability (%)
VC[c]	3338	89.6	59.6	89.4
VC	3343	88.5	64.8	87.3
VC	3346	82.2	65.5	91.5
DMN[d]	3337	89.5	74.3	92.5
DMN	3340	87.3	72.0	90.4
DMN	3348	78.4	64.7	93.4
5.50	3336	90.0	57.8	93.9
5.50	3342	88.6	71.2	92.0
5.50	3344	94.5	68.6	92.4
11.0	3334	92.3	48.5	92.1
11.0	3339	91.2	74.2	93.5
11.0	3349	87.8	70.2	91.2
22.0	3333	88.7	84.8	88.3
22.0	3347	86.8	70.4	83.1
22.0	3350	89.7	62.3	96.6
44.0	3335	91.9	83.6	92.9
44.0	3341	92.6	68.4	94.3
44.0	3345	91.3	56.9	90.8

[a] Three animals per dose were treated.
[b] Results based on viable counts (trypan blue dye exclusion) of randomly selected areas on two plates.
[c] VC = Vehicle Control (corn oil, 2 mL/kg).
[d] DMN = Dimethylnitrosamine 20 mg/kg).

A significant increase in S-phase DNA synthesis was determined by comparison with the average of the pooled vehicle control treatments. The test article was considered positive for replicative DNA synthesis because the percentage of cells in S-phase for all animals at 22.0 mg/kg and 11.0 mg/kg was significantly greater than the average number in the vehicle control cultures (Table 6-4). Significance was determined using a Student's t-test modified for unpaired observations with unequal variances when an F-test performed on the means determined that the variances were unequal. A standard t-test was used when the variances were equal. The increase in DNA synthesis appeared to be related to dose with the greatest increase occurring at 22.0 mg/kg. At both the highest dose (44.0 mg/kg) and the lowest dose (5.50 mg/kg) a single animal responded suggesting that variability in S-phase response might be related to toxicity of treament. A significant elevation in S-phase synthesis was observed in cells obtained from the positive control animals (DMN 20 mg/kg). The results provided evidence of the of induction of S-phase by the test article treatments at the 48-hour timepoint.

A significant elevation in S-phase synthesis was observed in treated animals sacrificed at the 15-h timepoint. During UDS analysis, 500 cells per slide (1500 cells per animal) were observed for S-phase. The elevation in S-phase synthesis was significant in comparison with the pooled vehicle control values in all animals receiving the 22.0 mg/kg dose. At both 44.0 mg/kg and 11.0 mg/kg, two of three animals responded. The response of the third animal at 44.0 mg/kg was not considered significant and may have been due to the variability between the three slides. S-phase response at this time may indicate early induction of toxicity leading to a proliferative response or may be due to a mitogenic stimulus. The results provide evidence of induction of S-phase by the test article treatment at the 15-h timepoint.

TABLE 6-4. S-PHASE DATA FOR HEPATOCTES FROM RATS[a]
TREATED WITH PFDA

Target Dose (mg/kg)	Animal Number	Total[b] S-Phase	Total[b] Cells Analyzed	% S-Phase ± SD
VC[c]	3346	24	6000	0.40 ± 0.22
VC	3343	25	6000	0.42 ± 0.06
DMN[d]	3340	110	6000	1.83 ± 0.53*
DMN	3337	127	6000	2.12 ± 0.98*
DMN	3348	55	6000	0.92 ± 0.13*
5.50	3344	88	6000	1.47 ± 0.38*
5.50	3342	53	6000	0.88 ± 0.35
5.50	3336	24	6000	0.40 ± 0.18
11.0	3349	143	6000	2.38 ± 0.95*
11.0	3339	84	6000	1.40 ± 0.22*
11.0	3334	70	6000	1.17 ± 0.44*
22.0	3347	160	6000	2.67 ± 0.64*
22.0	3333	137	6000	2.28 ± 0.44*
22.0	3350	100	6000	1.67 ± 0.81*
44.0	3335	32	6000	0.53 ± 0.08
44.0	3341	39	6000	0.65 ± 0.18
44.0	3345	87	6000	1.45 ± 0.13*

[a] Three animals per dose were treated.
[b] Triplicate coverslips, 2000 cells/coverslips.
[c] VC = Vehicle control (2 ml/kg of corn oil).
[d] DMN = Dimethylnitrosamine (20 mg/kg).
* Statistically significant difference compared to the average of the pooled vehicle controls $p < 0.05$.

CONCLUSIONS

PFDA did not induce significant changes in the UDS-associated nuclear labeling of rat primary hepatocytes for a dose range of about 5.5 to 44.0 mg/kg and was therefore evaluated as inactive in the *In Vivo/In Vitro* Rat Primary Hepatocyte UDS assay.

A significant S-phase response was observed in all animals treated with the test article at doses of 22.0 mg/kg and 11.0 mg/kg at both the 15-hour and 48-hour treatment times. PFDA was therefore evaluated as active in the *In Vivo/In Vitro* S-Phase Induction assay.

REFERENCES

Butterworth, B.E., J. Ashby, E. Bermudez, D. Casciano, J. Mirsalis, G. Probst, and G. Williams. 1987. A protocol and guide for the *in vivo* rat hepatocyte DNA-repair assay. *Mutation Res.*, 189:123-133.

Casciano, D.A. and D.W. Gaylor. 1983. Statistical criteria for evaluating chemicals as positive or negative in the hepatocytes DNA repair assay. *Mutation Research*, 122:81-86.

Mirsalis, J.C., C.K. Tyson, and B.E. Butterworth. 1982. Detection of genotoxic carcinogens in the *in vivo - in vitro* hepatocyte DNA repair assay. *Environ. Mutagenesis*, 4:553-562

Mirsalis, J.C. and B.E. Butterworth. 1982. Induction of unscheduled DNA synthesis in rat hepatocytes following *in vivo* treatment with dinitrotoluene. *Carcinogenesis*, 3:241-245.

Williams, G.M. 1980. The detection of chemical mutagens-carcinogens by DNA repair and mutagenesis in liver cultures. In: F. deSerres and A. Hollaender, eds. *Chemical Mutagens* Vol. 6, pp.61-79. Plenum Press, NY.

ASSAY ACCEPTANCE AND EVALUATION CRITERIA

Assay Acceptance Criteria

An assay normally will be considered acceptable for evaluation of the test results only if all of the criteria listed below are satisfied. This listing may not encompass all test situations, so scientific judgment must be exercised in modifying the criteria or considering other causes that might affect assay reliability and acceptance.

1. The viability of the hepatocytes collected from the perfusion process normally exceeds 70%. A variety of factors can affect cell yield and viability, so values below 70% are not uncommon nor necessarily detrimental. Toxicity of treatment with test article may be reflected in perfusion viability, therefore no lower limit will be set.

2. The viability of the monolayer cell cultures used for the assay must be 70% or greater. Normally, the viability of attached cells is about 85%.

3. The positive control is used to demonstrate that the cell population employed was responsive and the methodology was adequate for the detection of UDS or S-phase. For test materials causing weak or no UDS activity, the average response to the positive control treatments must exceed either criteria used to indicate UDS. The positive control for S-phase must have greater than 1% of the cells in scheduled DNA synthesis. For test materials clearly causing a dose-related UDS activity or S-phase activity, an assay will be acceptable in the absence of a positive control lost for technical reasons. Historical values for the UDS positive control are NNG = 8.79 ± 3.92 (range, 1.55 to 15.40) and % ≥ 5 grains per nucleus = 62.7% ± 18.2% (range 20.7% to 89.7%). Historical control values for the UDS negative control are NNG = -0.54 ± 0.50 (range, -1.74 to 0.12) and % ≥ 5 grains per nucleus = 1.4% ± 1.7% (range 0.0% to 6.7%).

4. Grain count data obtained per animal is acceptable as part of the evaluation if obtained from two replicate cultures and at least 50 nuclei per culture for UDS or 2000 cells per culture for S-phase. Data should be available from 2 of the 3 animals treated.

5. A minimum of three doses will be analyzed for nuclear grain counts. Repeat trials need only augment the number of analyzed doses in the first trial to achieve a total of 3 concentrations, but must include one dose previously analyzed as acceptable.

Assay Evaluation Criteria

UDS Assay

Several criteria have been established which, if met, provide a basis for evaluation of a test material as active in the UDS assay. The criteria for a positive response are based on a statistical analysis of the historical control data as described by Casciano and Gaylor (1983). The test material is considered active in the UDS assay at doses that cause the following.

1. An increase in the mean net nuclear grain count to at least five grains per nucleus above the concurrent vehicle control value leading to a positive number, and/or;

2. An increase in the number of nuclei having five or more net grains such that the percentage of these nuclei in test cultures is 10% above the concurrent vehicle control cultures.

Generally, if the first condition is satisfied, the second will also be met. However, satisfaction of only the second condition can also indicate UDS activity. Different DNA-damaging agents can give a variety of nuclear labeling patterns, and weak agents may strongly affect only a minority of the cells. Therefore, both of the above conditions are considered in an evaluation. In cases where increases are not observed in all three animals, the test material will be considered active for that condition if cells from two of the three animals show increases. If the negative control shows an average less than -5 or more than one grain per nucleus, the assay will normally be considered invalid.

The test material is considered inactive in this assay if the following is true.

1. The mean net nuclear grain counts for all dosed groups is < 1.0 net nuclear grain count above the concurrent vehicle control value and/or;

2. The percent of nuclei with five or more net grains does not increase more than 2% above the concurrent vehicle control.

When results are neither clearly positive nor clearly negative, the presence of a dose response, the frequency distribution of cellular responses, and the reproducibility of data among animals is considered; the test article is then classified as "negative", "weak positive", or "equivocal". Groups in which one of three animals shows increases in labeling will be decided on a case by case basis depending on the level of activity in cells from the active animal, the level of activity in cells from the inactive animals and the presence or absence of activity in surrounding groups.

The positive control nuclear labeling is not used as a reference point to estimate mutagenic or carcinogenic risk associated with the UDS activity of the test material. UDS elicited by test agents in this assay is probably more dependent on the type of DNA damage inflicted and the available repair mechanisms than on the potency of the test agent as a mutagen or carcinogen. Some forms of DNA damage are repaired without the incorporation of new nucleic acids. Thus, the positive controls are used to demonstrate that the cell population employed was responsive and the methodology was adequate for the detection of UDS.

S-Phase Induction Assay

The test article will be considered positive in the S-phase induction assay if the %S in cells from all animals in a group is significantly greater than the pooled vehicle control and exceeds 1% of the population. Significance will be determined using Student's t-test for unpaired observations modified for unequal variances when an F-test performed on the data indicates that the variances were unequal. A standard t-test will be used when the variances are equal.

The test article will be considered negative if the % S for all treatment groups is < 1.0% of the population (historical negative controls have < 1% of the cells undergoing DNA replication). The data base for S-phase is not extensive and some judgement may be needed in the evaluation of a response.

IN VITRO TRANSFORMATION OF BALB/C-3T3 CELLS WITH AND WITHOUT S9 ACTIVATION OF PFDA

B.C. Myhr

ABSTRACT

PFDA was assayed for its ability to induce morphological cell transformation in BALB/c-3T3 cell cultures in the absence and presence of a rat liver S9 metabolic activation system. Two independent assays were performed without metabolic activation and three were performed in the presence of metabolic activation. The treatment period was 72 h without activation and 4 h in the presence of S9 metabolic activation. In the absence of an S9 metabolic activation system, six doses ranging from 40 to 140 $\mu g/mL$ were initiated in two trials. The toxicity, determined from the clonal survival of ouabain-resistant cells in the presence of a wildtype monolayer, ranged from essentially nondetectable to 100%. The number of transformed foci in the PFDA-treated cultures did not change significantly from the corresponding negative controls. In the presence of S9 metabolic activation, a shift in toxicity was observed and treatments from 50 to 650 $\mu g/mL$ were initiated. In the first complete trial analyzed, a sharp toxicity curve resulted in no cultures with cells in the 10% to 50% survival range. For this reason, two more trials were performed. The results from these trials showed a good range of toxicities that included several doses in the appropriate toxicity range. None of the cultures treated with PFDA resulted in a significant increase in transformed foci in any of the three trials. PFDA was therefore evaluated as negative for the induction of morphological transformation in BALB/c-3T3 cell cultures.

INTRODUCTION

BALB/c-3T3 mouse cells multiply in culture until a uniform monolayer is achieved and then cease further division (Kakunaga, 1973; Rundell, 1984b). These nontransformed cells, if injected into immunosuppressed mice (1×10^7 cells/animal), do not produce neoplastic tumors (Kakunaga, 1973; Rundell et al., 1983; Rundell, 1984a). However, BALB/c-3T3 cells treated in vitro with some chemical carcinogens give rise to foci of morphologically altered cells superimposed on the contact-inhibited cell monolayer. If foci picked from cell cultures are grown to larger cell numbers and are injected into immunosuppressed mice, a malignant tumor will be obtained in most cases. Thus, the appearance of foci of altered cells is correlated with malignant transformation.

The ability of BALB/c-3T3 cells to metabolize test articles from various chemical classes can be enhanced by the addition of an exogenous S9 metabolic activation system to the cultures during the treatment period. However, the standard treatment period of 72 h is reduced to only 4 h because of S9 toxicity and the degradation of the NADPH-dependent microsomal enzyme system, so this assay modification may not always detect procarcinogens. The procarcinogen, DMN, does not transform BALB/c-3T3 cells in the absence of S9 (Rundell et al., 1983), but DMN treatments with the S9 activation system usually induce a statistically significant increase in the frequency of transformed foci (Matthews and Rundell). Similarly, S9-dependent induction of transformed foci by DMN has been reported for another mouse line (Tu et al., 1984).

An appropriate dose range for toxic test articles is selected by a novel method for determining clonal survival under the mass culture conditions of the transformation assay. Normal BAL3/c-3T3 cells are sensitive to the cell membrane poison, ouabain, and are quickly killed. However, a mutant BALB/c-3T3 cell line has been established that is ouabain-resistant but otherwise as sensitive to test articles as the parent (wildtype, ouabain-sensitive cells). When a few (eg., 600) ouabain-resistant cells are mixed with a large number of wildtype cells (eg., 7×10^4 cells), the clonal survival of the ouabain-resistant cells can be determined by the addition of 4 mM ouabain to the culture medium after the treatment period. In this manner, the test article toxicity is determined under the same cellular exposure conditions that will occur in the transformation assay mass cultures.

The objective of this assay was to evaluate PFDA for its ability to induce the malignant transformation of cultured BALB/c-3T3 mouse cells in the absence and presence of a rat liver S9 metabolic activation system. Transformation has been defined as a dense, piling up of morphologically altered cells, called a focus, superimposed on a monolayer of contact-inhibited cells (Heidelberger et al., 1983; Rundell, 1984a;b).

MATERIALS AND METHODS

Indicator Cells

Clone 1-13 of BALB/c-3T3 mouse cells was obtained (Kakunaga, 1973). A subclone of these cells with a low spontaneous frequency of transformants was used for this study. Stocks of cells were maintained in liquid nitrogen and were checked to ensure the absence of *Mycoplasma* contamination. Laboratory cell cultures were grown in Eagle's minimum essential medium (EMEM) supplemented with FBS, L-glutamine, and antibiotics.

Controls

The negative control (also referred to as the solvent control) was EMEM culture medium containing DMSO (0.25% v/v). In addition, for the S9 activation assay, the S9 activation system was added to the medium.

A known carcinogen, MCA, was used at a concentration of 2.5 µg/mL as a positive control for the transformation of BALB/c-3T3 cells in the absence of S9. A second known carcinogen, DMN, was used as the positive control for the transformation of BALB/c-3T3 cells in the presence of S9 activation. DMN requires activation by S9 microsomal enzymes to become transforming, and two concentrations of DMN (1 and 2 µL/mL) were chosen to demonstrate a significant response for at least one concentration of DMN.

Test Material

The test material, PFDA, was a white crystalline solid that formed flakes and was electrostatic. It was stored at room temperature in its original glass container in a chemical cabinet.

S9 Metabolic Activation System

A 9000 x g supernatant fraction (Ames et al., 1984) prepared from the liver of Aroclor 1254-induced Sprague-Dawley male rats was purchased from Molecular Toxicology Inc. The S9 was prescreened and selected for relatively low toxicity to BALB/c-3T3 cells and for the conversion of DMN to toxic metabolites. The concentration of S9 selected for the assay was 40 µL/mL that corresponded to 1.5 mg S9 protein/mL in the treatment medium.

The S9 activation components included a NADPH regenerating system composed of NADP and isocitric acid in the presence of S9. The final concentration of the components in the treatment medium was approximately 236

μg/mL of NADP (sodium salt) and approximately 1552 μg/mL of isocitrate. The regenerating system solution was prepared fresh as a 4X stock solution in culture medium and was combined with an equal volume of diluted S9 to give a 2X S9 mix. The mix was held on ice until used in the assay.

Test Material Preparation

PFDA was soluble in DMSO up to a concentration of 400 mg/mL. The primary stocks for the cytotoxicity and transformation assays were diluted in EMEM containing 10% v/v FBS (EMEM10) to prepare 2X dosing solutions and further dilutions were prepared in EMEM10 containing 0.5% DMSO. The primary medium stocks ranging from 500 to 2000 μg/mL were cloudy and no pH change was evident. The cultures were dosed by adding 4 mL of the appropriate dosing medium to 4 mL of EMEM10 already present in the culture flasks.

Preliminary Dose Rangefinding

Glass culture bottles with approximately 60 cm^2 of surface area were seeded concurrently with approximately 600 ouabain-resistant 3T3 cells and 7 x 10^4 wildtype cells. The following day, one culture was exposed to each of 10 doses with and without S9, starting at 1000 μg/mL and diluting in 2-fold steps. Two solvent control cultures containing 0.25% DMSO in EMEM(10) culture medium were prepared for both test conditions. After an exposure period of approximately 4 h in the presence of the S9 activation system or approximately 72 h without S9, the cells were washed with a physiological solution and refed with EMEM(10) culture medium containing 4 mM ouabain. The cultures were refed with medium containing 4 mM ouabain 4 to 5 days later. Surviving colonies were terminated 11-12 days after the treatment period, stained with Giemsa, and counted manually.

A relative survival for each treatment condition was obtained by comparing the number of surviving colonies to the average colony count for the solvent control cultures. This survival information was used to select doses for the transformation assay that would span an anticipated survival range of 10 to 100%.

Transformation Assay

The transformation assay procedure was adapted from that reported by Kakunaga (1973). Glass culture bottles having a monolayer growth area of approximately 60 cm^2 were used. Each bottle was seeded with approximately 7 x 10^4 cells for the transformation assay and 7 x 10^4 cells plus approximately 600 ouabain-resistant cells for the concurrent clonal survival assay. On the day after seeding, nine cultures were exposed to each selected treatment with PFDA and the positive controls. Eighteen cultures were used as solvent controls for each of the test conditions (with and without the S9 activation system). One mixed culture of wildtype and ouabain-resistant cells was exposed to each treatment and positive control condition; two mixed cultures were included for the solvent controls.

The treatments were conducted at 37 ± 1°C for approximately 4 h with the S9 activation system and approximately 72 h without S9. The treatments were initiated by adding 4 mL of a 2X stock of PFDA or solution of the positive control to each culture containing 4 mL of culture medium (with or without the S9 activation system). After treatment, all cultures were washed with Hanks' balanced salt solution. The transformation assay cultures were refed with fresh EMEM culture medium, and the incubation was continued for 28 to 34 days with refeeding twice a week. The activation studies were incubated slightly longer to allow adequate expression of the transformed colonies. The clonal

survival cultures were refed with medium containing 4 mM ouabain. The cultures were refed with 4 mM ouabain 4 days later if needed and were terminated when the colonies reached a size that could be easily scored.

The cultures were terminated by fixing the cells with methanol and staining with 10% Giemsa in tap water. Stained cultures were examined by eye and by microscope to determine the number of foci of transformed cells and the colony survival. The transformation assay cultures were coded with random numbers prior to evaluation for foci.

Evaluation of Transformed Foci

At the end of the incubation period, cultures of cells with a normal phenotype yielded a uniformly stained monolayer of round, contact-inhibited cells. Transformed cells formed a multi-layered mass of cells, or focus, that stained deeply and was superimposed on the surrounding monolayer of cells (Kakunaga, 1973; Rundell et al., 1983; Rundell 1984a). The foci were variable in size and exhibited several variations in morphological features. Many scored foci consisted of a dense piling-up of cells with a random, criss-cross orientation of fibroblastic cells at the periphery of the focus and extensive invasiveness into the contiguous monolayer. Other scored foci were composed of more rounded cells with little criss-crossing at the periphery but with necrosis at the center caused by the dense piling-up of a large number of cells. A third variation was a focus without the necrotic center and large number of cells but which exhibited the criss-cross pattern of overlapping cells throughout most of the colony.

Some densely stained areas were not scored as transformed foci because the random orientation of fibroblastic cells was not observed. Microscopic examination is routinely employed for scoring and for the final judgement of the transformed character of each focus.

All foci that exhibited the transformed characteristics were scored. In the raw data, a record of focus size was maintained by scoring foci greater than 4 mm in diameter as +++ and those of 2 to 4 mm in diameter as ++. No significance is currently attached to this categorization. The sum of all scored foci (+++ and ++) was reported for each culture and was used for the assay analysis.

RESULTS AND DISCUSSION

Clonal Survival

PFDA was lethal to BALB/c-3T3 cells at and above concentrations of 100 μg/mL in the absence of metabolic activation. Lower concentrations were nontoxic (Table 7-1). The addition of the rat liver S9 metabolic activation system caused a shift in toxicity. The test material was lethal at a concentration of 1000 μg/mL and the survival increased to 80.6% when the concentration was reduced to 500 μg/mL (Table 7-2). Lower concentrations were nontoxic. These results were used to choose doses for the transformation assay and results from the early transformation assays were used to further define the dose range. For the nonactivation studies used in the evaluation, treatments ranging from 40 to 140 μg/mL were initiated. In the presence of S9 metabolic activation, treatments ranging from 50 to 650 μg/mL were initiated.

TABLE 7-1. CYTOTOXIC ACTIVITY OF PFDA IN THE PRELIMINARY CLONAL SURVIVAL ASSAY WITHOUT S9 ACTIVATION

Treatment Condition	Colonies/Culture	Relative Cell Survival (%)
Solvent Control[a]	221, 211	100.0
PFDA (µg/mL)		
1.00	221	102.3
2.50	226	104.6
5.00	235	108.8
10.0	200	92.6
25.0	213	98.6
50.0	232	107.4
100	0	0.0
250	0	0.0
500	0	0.0
1000	0	0.0

[a] EMEM culture medium containing 0.25% DMSO.

TABLE 7-2. CYTOTOXIC ACTIVITY OF PFDA IN THE PRELIMINARY CLONAL SURVIVAL ASSAY WITH S9 ACTIVATION

Treatment Condition	Colonies/Culture	Relative Cell Survival (%)
Solvent Control[a]	102, 99	100.0
PFDA (µg/mL)		
1.00	96	95.5
2.50	26	25.9
5.00	102	101.5
10.0	110	109.5
25.0	101	100.5
50.0	94	93.5
100	113	112.4
250	107	106.5
500	81	80.6
1000	0	0.0

[a] EMEM culture medium containing 0.25% DMSO.

Preliminary Transformation Studies

Five transformation assays conducted in the absence of S9 metabolic activation were initiated, but the first two trials were subsequently terminated without the collection of any valid data because of the observation of numerous transformed foci in the negative control cultures. The third assay was terminated due to contamination and no data was available. The data from the fourth and fifth assays are reported in Table 7-3 and 7-4, respectively. In the presence of S9 metabolic activation, eight trials were initiated. Trials 1, 2, 3, 4, and 6 were terminated without the collection of

valid data because of technical problems (numerous foci in the negative control cultures, contamination, or excessive toxicity). In Trial 5, the assay did not include doses resulting in a 10% to 50% survival because of a very sharp toxicity curve. These data are presented in Table 7-5. The remaining two trials resulted in acceptable survivals and the data are reported in Table 7-6 and Table 7-7, respectively.

The presence of excessive transformed colonies in the solvent control cultures in some of the early trials resulted in the temporary interruption of this study until the reason(s) could be identified and eliminated. After several months, a new lot of FBS for the culture medium was identified that afforded normal behavior for the negative control cultures. This serum and a fresh batch of cells from the cryopreserved stock were used to reinitiate the study.

Transformation Assay Without S9

Table 7-3 summarizes the results obtained for PFDA in the first complete trial of the transformation assay without S9. In Trial 1, six treatments ranging from 40 to 140 μg/mL were initiated. The culture exposed to 140 μg/mL treatment could not be analyzed because of excessive toxicity. The remaining five treatments induced a wide range of toxicities (35.9 to 93.2% relative survival). The frequency of transformed foci in the cultures exposed to PFDA was not significantly elevated above the solvent control values. In contrast, the MCA positive control induced a significant increase in focus formation. In order to confirm the lack of activity by PFDA a second nonactivation assay was initiated.

Results from the second complete trial without S9 are presented in Table 7-4. Seven treatments ranging from 50 to 140 μg/mL were initiated in Trial 2. Both the 140 μg/mL and 130 μg/mL treatments were excessively toxic and could not be analyzed. Survivals of the remaining five treatments ranged from 15.5 to 102.6% of the solvent control value. No significant increase in transformed foci was observed in any of the test article-treated cultures. The MCA positive control induced a large, significant increase in transformed foci. Because no significant increase in transformed foci was induced by PFDA in two trials of the BALB/c-3T3 transformation assay, the test material was evaluated as nontransforming in the absence of S9 metabolic activation.

Transformation Assay with S9

The results obtained for PFDA in the first completed trial of the transformation assay with S9 are summarized in Table 7-5. In Trial 1, eight treatments ranging from 50 to 650 μg/mL were initiated. The treatments at concentrations of 650, 600, and 550 μg/mL could not be analyzed because of excessive toxicity. The culture exposed to a concentration of 500 μg/mL formed a good monolayer and the dose was analyzed despite a 5.9% relative survival. When the concentration of the test article was reduced to 250 μg/mL, the survival increased to 96.8%. No significant increase in the number of transformed foci were observed in any of the PFDA-treated cultures but no treatments resulted in the 10% to 50% survival range where activity is usually observed. Both of the DMN positive controls clearly induced foci. A second assay was initiated in the presence of S9 metabolic activation to clarify the response with doses in the desired toxicity range.

TABLE 7-3. TRANSFORMING ACTIVITY OF PFDA ASSESSED IN THE TRANSFORMATION ASSAY USING BALB/c-3T3 CELLS WITHOUT S9 ACTIVATION

TRIAL 1

Treatment Condition	Colony Count[a,b]	Relative Survival[c] (%)	Focus Data			Transforming[d] Activity
			Total Cultures	Total Foci	Average Foci/ Culture	Mean Foci/ Culture
Solvent Control[e]	295	100.0	18	1	0.06	0.04
Positive Control[f]	193	65.4	9	34	3.78	3.65**
PFDA (μg/mL)						
40.0	275	93.2	9	0	0.00	0.00
60.0	249	84.4	9	0	0.00	0.00
80.0	272	92.2	9	1	0.11	0.08
100	195	66.1	9	1	0.11	0.08
120	106	35.9	9	0	0.00	0.00
140	NOT SCORED DUE TO EXCESSIVE TOXICITY					

[a] Clonal survival assay performed concurrently with the transformation assay.

[b] There were 2 cultures (averaged) for the solvent control and 1 culture for all other conditions.

[c] Colony survival relative to the solvent control.

[d] The mean transforming activity is expressed as the anti-log of the $\log_{10}$ mean minus one.

[e] Solvent Control: EMEM culture medium containing 0.25% DMSO.

[f] Positive Control: The positive control treatment was MCA (2.5 μg/mL).

** $p < 0.01$.

TABLE 7-4. TRANSFORMING ACTIVITY OF PFDA ASSESSED IN THE TRANSFORMATION ASSAY USING BALB/c-3T3 CELLS WITHOUT S9 ACTIVATION TRIAL 2

Treatment Condition	Colony Count[a,b]	Relative Survival[c] (%)	Focus Data			Transforming[d] Activity
			Total Cultures	Total Foci	Average Foci/ Culture	Mean Foci/ Culture
Solvent Control[e]	348	100.0	18	16	0.89	0.66
Positive Control[f]	157	45.1	9	40	4.44	4.38**
PFDA (μg/mL)						
50.0	354	101.7	9	9	1.00	0.79
75.0	357	102.6	7[g]	6	0.86	0.74
100	235	67.5	8[g]	8	1.00	0.86
110	268	77.0	9	6	0.67	0.47
120	54	15.5	8[h]	0	0.00	0.00
130	40	11.5	NOT SCORED DUE TO INCOMPLETE MONOLAYERS.			
140	2	0.6	NOT SCORED DUE TO INCOMPLETE MONOLAYERS.			

[a] Clonal survival assay performed concurrently with the transformation assay.
[b] There were 2 cultures (averaged) for the solvent control and 1 culture for all other conditions.
[c] Colony survival relative to the solvent control.
[d] The mean transforming activity is expressed as the anti-log of the $\log_{10}$ mean minus one.
[e] Solvent Control: EMEM culture medium containing 0.25% DMSO.
[f] Positive Control: The positive control treatment was MCA (2.5 μg/mL).
[g] Contaminated cultures excluded.
[h] One culture not scored due to incomplete monolayer.
** $p < 0.01$

Table 7-6 summarizes the results obtained in the second trial. In Trial 2, seven treatments ranging from 300 to 500 μg/mL were initiated and a good range of toxicities was induced. Treatment at a concentration of 500 μg/mL appeared lethal in the cytotoxicity portion of the assay but enough cells survived that a monolayer formed and analysis was possible. The remaining six treatments induced a good range of toxicities including two which resulted in a survival of between 10% and 50%. No significant increase in the number of transformed foci was observed in any of the cultures treated with the test material. In contrast, both the DMN positive control treatments induced a large increase in transformed foci that were significant at the 99% confidence level. PFDA was therefore evaluated as inactive in this assay in the presence of S9 metabolic activation. A third activation assay was initiated to confirm these results.

In the third complete transformation assay performed in the presence of S9 metabolic activation (Table 7-7), seven treatments from ranging from 300 to 500 μg/mL were initiated. This assay confirmed the absence of transforming activity by PFDA. The 500 μg/mL treatment was excessively toxic and could not be analyzed. The remaining six treatments resulted in relative survivals ranging from 5.0 to 86.0%. None of the treatments induced a significant

elevation in transformed foci. In contrast, both positive control treatments with DMN induced a large increase in transformed foci. PFDA was therefore evaluated as nontransforming to BALB/c-3T3 cells.

TABLE 7-5. TRANSFORMING ACTIVITY OF PFDA ASSESSED IN THE TRANSFORMATION ASSAY USING BALB/c-3T3 CELLS WITH S9 ACTIVATION TRIAL 1

Treatment Condition	Colony Count[a,b]	Relative Survival[c] (%)	Focus Data			Transforming[d] Activity
			Total Cultures	Total Foci	Average Foci/ Culture	Mean Foci/ Culture
Solvent Control[e]	187	100.0	18	12	0.67	0.51
Positive Control[f]						
DMN, 1 μL/mL	114	61.0	9	21	2.33	1.94**
DMN, 2 μL/mL	108	57.8	9	38	4.22	3.33**
PFDA (μg/mL)						
50.0	173	92.5	9	2	0.22	0.17
75.0	209	111.8	9	2	0.22	0.13
125	157	84.0	9	5	0.56	0.47
250	181	96.8	9	0	0.00	0.00
500	11	5.9	9	0	0.00	0.00
550	3	1.6	NOT ANALYZED DUE TO EXCESSIVE TOXICITY.			
600	0	0.0	NOT ANALYZED DUE TO EXCESSIVE TOXICITY.			
650	0	0.0	NOT ANALYZED DUE TO EXCESSIVE TOXICITY.			

[a] Clonal survival assay performed concurrently with the transformation assay.
[b] There were 2 cultures (averaged) for the solvent control and 1 culture for all other conditions.
[c] Colony survival relative to the solvent control.
[d] The mean transforming activity is expressed as the anti-log of the $\log_{10}$ mean minus one.
[e] Solvent Control: EMEM culture medium containing 0.25% DMSO.
[f] Positive Control: The positive control treatment was DMN at the concentrations shown.
** $p < 0.01$.

72

TABLE 7-6. TRANSFORMING ACTIVITY OF PFDA ASSESSED IN THE TRANSFORMATION ASSAY USING BALB/c-3T3 CELLS WITH S9 ACTIVATION

TRIAL 2

Treatment Condition	Colony Count[a,b]	Relative Survival[c] (%)	Focus Data			Transforming[d] Activity
			Total Cultures	Total Foci	Average Foci/ Culture	Mean Foci/ Culture
Solvent Control[e]	203.5	100.0	18	11	0.61	0.48
Positive Control[f]						
DMN, 1 μL/mL	173	85.0	9	48	6.00	5.61**
DMN, 2 μL/mL	135	66.3	6[g]	37	6.17	5.33**
PFDA (μg/mL)						
300	186	91.4	8[g]	11	1.38	1.21
350	185	90.9	8[g]	6	0.75	0.49
400	108	53.1	9	3	0.33	0.26
425	72	35.4	8[g]	5	0.63	0.49
450	80	39.3	9	5	0.56	0.42
475	11	5.4	9	8	0.89	0.66
500	0	0.0	9	6	0.67	0.54

[a] Clonal survival assay performed concurrently with the transformation assay.

[b] There were 2 cultures (averaged) for the solvent control and 1 culture for all other conditions.

[c] Colony survival relative to the solvent control.

[d] The mean transforming activity is expressed as the anti-log of the $\log_{10}$ mean minus one.

[e] Solvent Control: EMEM culture medium containing 0.25% DMSO.

[f] Positive Control: The positive control treatment was DMN at the concentrations shown.

[g] Contaminated culture or cultures excluded.

** $p < 0.01$.

TABLE 7-7
TRANSFORMING ACTIVITY OF PFDA ASSESSED IN THE
TRANSFORMATION ASSAY USING BALB/c-3T3 CELLS
WITH S9 ACTIVATION
TRIAL 3

Treatment Condition	Colony Count[a,b]	Relative Survival[c] (%)	Focus Data		Average Foci/ Culture	Transforming[d] Activity Mean Foci/ Culture
			Total Cultures	Total Foci		
Solvent Control[e]	222	100.0	18	19	1.06	0.71
Positive Control[f]						
DMN, 1 μL/mL	157	70.7	9	40	4.44	3.95**
DMN, 2 μL/mL	124	55.9	9	27	3.00	2.63**
PFDA (μg/mL)						
300	191	86.0	9	3	0.33	0.22
350	178	80.2	9	2	0.22	0.17
400	168	75.7	9	4	0.44	0.32
425	144	64.9	9	6	0.67	0.49
450	124	55.9	9	7	0.78	0.61
475	11	5.0	9	8	0.89	0.66
500	6	2.7	NOT ANALYZED DUE TO EXCESSIVE TOXICITY.			

[a] Clonal survival assay performed concurrently with the transformation assay.
[b] There were 2 cultures (averaged) for the solvent control and 1 culture for all other conditions.
[c] Colony survival relative to the solvent control.
[d] The mean transforming activity is expressed as the anti-log of the $\log_{10}$ mean minus one.
[e] Solvent Control: EMEM culture medium containing 0.25% DMSO.
[f] Positive Control: The positive control treatment was DMN at the concentrations shown.
** $p < 0.01$.

CONCLUSION

PFDA was evaluated within a dose range of from 40.0 to 140 μg/mL in the absence of S9 metabolic activation and from 50.0 to 650 μg/mL in the presence of a rat liver S9 metabolic activation system. Two independent trials were evaluated under nonactivation conditions and three in the presence of S9 activation. A wide range of toxic responses was obtained, but no significant change in the frequency of transformed foci was observed in the absence or presence of S9 metabolic activation. PFDA was therefore evaluated as negative for transforming BALB/c-3T3 cells in culture.

REFERENCES

Ames, B.N., W.E. Durston, E. Yamasaki, and F.D. Lee. 1984. Carcinogens are mutagens; a simple test system combining liver homogenates for activation and bacteria for detection. *Proc. Natl. Acad. Sci. USA* 78:6858-6862.

Bailey, Normal T.J. 1959. *Statistical Methods in Biology.* Wiley and Sons, Inc., NY, p. 50.

Heidelberger, C., A.E. Freeman, R.J. Pienta, A. Sivak, J.S. Bertram, B.C. Casto, V.C. Dunkel, M.W. Francis, T. Kakunaga, J.B. Little, and L.M. Schechtman. 1983. Cell transformation by chemical agents – a review and analysis of the literature. *Mutat. Res.* 114:283-385.

Kakunaga, T. 1973. A quantitative system for assay of malignant transformation by chemical carcinogens using a clone derived from BALB/3T3. *Int. J. Cancer* 12:463-473.

Matthews, E.J. and J.O. Rundell. S9-mediated activation of procarcinogens to cytotoxic, mutagenic, and transforming intermediates for BALB/c-3T3 cells. Prepared manuscript.

Rundell, J.O., M. Guntakatta, and E.J. Matthews. 1983. Criterion development for the application of BALB/c-3T3 cells to routine testing for chemical carcinogenic potential. In: M.D. Water, et al. (eds.) *Short-term Bioassays in the Analysis of Complex Environmental Mixtures III*. Plenum Publishing Co., NY, pp. 309-327.

Rundell, J.O. 1984a *In vitro* transformation assays using mouse embryo cell lines: BALB/c-3T3 cells. In: J.F. Douglas (ed.) *Carcinogenesis and Mutagenesis Testing*. Humana Press, pp. 279-285.

Rundell, J.O. 1984b. *In vitro* cell transformation, an overview. In: J.F. Douglas (ed) *Carcinogenesis and Mutagenesis Testing*. Humana Press, pg. 39-61.

Tu, A.S., P.A. Green, and A. Sivak. 1984. Comparison of primary hepatocytes and S9 metabolic activation systems for the C3H10T½ cell transformation assay. *Carcinogenesis* 5:1431-1436.

Whorton, E.B., J.B. Ward, and D.L. Morris. 1982. Experimental design and statistical analysis considerations for *in vitro* mammalian cell transformation assays with BALB/c-3T3 cells. *Environ. Mutagen.* 4:595-603.

APPENDIX 7-A

ASSAY ACCEPTANCE AND EVALUATION CRITERIA

Assay Acceptance Criteria

The clonal survival assay conducted simultaneously with the transformation assay was considered acceptable for evaluation of the test results by meeting the following three criteria.

1. The negative (solvent) control cultures were macroscopically visible BALB/c-3T3 cell colonies representing a cloning efficiency of 15% or greater.

2. At least one of the test material treatments resulted in 10% to 50% cell survival.

3. A cytotoxic dose response was obtained for the test material treatments, unless the test material was nontoxic at 10 mg/mL or its solubility limit in culture medium was exceeded.

The transformation assay was considered acceptable for evaluation of test results by meeting the following five criteria.

1. Negative (solvent) control, positive control, and test material treatments resulted in contiguous monolayers of cells to be evaluated.

2. Negative control spontaneous frequencies of transformation did not exceed an average of approximately two foci per culture.

3. At least one of the positive control treatments resulted in an average number of foci per culture vessel that was significantly different from the negative control at the 99% confidence level ($p \leq 0.01$).

4. A minimum number of six culture vessels per test condition was available for analysis.

5. A minimum number of three treatment levels of the test material was available for analysis.

In addition, the cytotoxicity dose-related data from the preliminary and simultaneous clonal survival assays were qualitatively similar over a comparable range of test chemical treatments.

Assay Evaluation Criteria

The appearance of transformed foci usually occurs as a general increase in foci for all cultures exposed to a transforming dose level. However, large numbers of foci may appear at random in one or more culture vessels in a treatment set, resulting in skewing of the mean number of foci in that set. This skewing could be caused by factors such as mechanical disruption and respreading of transformed foci cells or a culture-conditioning effect caused by the early appearance of a focus. The appearance of occasional dishes with numerous foci is a random process and occurs in both treated and control cell cultures. In our laboratory, we have utilized a $\log_{10}$ mathematical transformation to handle this non-normal distribution of BALB/c-3T3 cell

transformed foci data (Rundell et al., 1983); however, other mathematical models have also been proposed (Whorton et al., 1982). After performing a $\log_{10}$ transformation of the data, Bailey's modification of the Student's t-test (Bailey, 1959) was used to evaluate positive control and test chemical treatment transforming activity for significant differences from the negative control. The possible spectrum of responses was routinely subdivided into three levels for the evaluation of each treatment.

Evaluation of Individual Treatments

Strong positive response $=$ $p \leq 0.01$
Weak positive response $=$ $p \leq 0.05$
Negative response $=$ $p > 0.05$

The results of each treatment condition were evaluated in relation to the observed activities of model compounds, and scientific judgement was exercised in the evaluation of each test material.

In general, a response at only one dose level attaining a 95% confidence level is not considered sufficient evidence for activity in this assay. However, responses at two or more treatment levels attaining the 95% confidence level and exhibiting evidence of a dose relationship are considered as evidence for transformation. Responses achieving the 99% confidence level for one or more test material treatments are usually considered sufficient for a positive evaluation.

77